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Abstract 
 
Cannabis, commonly known as marijuana, has a rich history as a source of fiber, food 
and medicine (Li 437). Since 1785, physicians and scientists alike have worked to discover the 
active chemical components and medical effectiveness of this plant (Touw 2; Aldrich). Despite 
its complicated legal history, marijuana has retained a place culturally and, in some countries, 
scientifically as an effective medical agent. As a medically edible ingredient, cannabis has also 
been more recently heralded as a new, even cutting edge flavor, opening a new frontier to the 
culinary community.  
After the isolation of the main active ingredient in cannabis, δ-9 tetrahydrocannabinol 
(THC), in 1964, various physicians and scientists conducted research demonstrating its 
therapeutic medical efficacy for a variety of illnesses including glaucoma, cancer, AIDS, 
anorexia, Crohn’s disease, multiple sclerosis, and pain management (Watson et. al. 548). Over a 
decade has passed since cannabis first became legalized for medical use in California in 1996 
(Eddy 8). Subsequently, 18 other states, including the District of Columbia, legalized cannabis 
for medical use.  
Individuals who have received a doctor’s recommendation for its use are authorized to 
consume cannabis for medical purposes. Although it is commonly ingested by inhalation, many 
individuals prefer to consume marijuana through edible products. Due to an increased interest in 
careful cultivation practices, biochemical evaluation of the product, and quality control efforts, a 
market for medical edibles has developed.  Many chefs have begun experimenting with cannabis, 
using it as a spice or flavor, to create a sensory food experience. Savvy chefs, such as Scott Van 
Rixel, Kristi Knoblich, Eric Underwood, Julie Dooley and Julianna Carella entered this new 
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market with both entrepreneurial and altruistic interest in creating medical marijuana edibles, 
tapping into the new flavor frontier this product provides. 
It is interesting that in the culinary world’s constant search for new and exciting flavor 
discoveries, the medical edibles industry has not received much mainstream interest. Little data 
has been compiled supporting the potential this ancient plant may bring to cuisine (Watson et. al. 
548). Now, due to the application of ancient and experimental techniques, these innovative chefs 
are blazing the trail for the culinary community.  
This paper investigates edible medical marijuana as a viable frontier and niche market 
from a legal, medical and culinary perspective. It reviews the etymology and the history of 
cannabis, as well as current legal, medicinal and cultivation guidelines. This is accomplished 
through an overview of four states’ dispensary policies, as well as the creative culinary 
accomplishments of representative edible establishments. This study also draws on the results of 
two surveys: one directed to the edible product developers, dispensers, and vendors, the other 
survey directed to authorized patients of the dispensaries. The data collected is intended to 
confirm the emergence of a unique culinary product, its value, increased distribution, and 
potential for success in this newly developed market.  
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Chapter One: Introduction 
 
Early civilizations discovered medicinal, nutritional and functional uses for their 
indigenous vegetation.  Tinctures, extracts or oils derived from plants and served in edible or 
beverage form became the basis of remedies for treating illness. The relationship between food 
and medicine was thoroughly intertwined. Of the myriad of plants used in this early medical 
arsenal, cannabis is steeped in controversy, touted in the United States as a nefarious drug by 
federal regulators as well as a bona fide medicinal agent by patients, doctors, and current medical 
research.  
Accepted as a therapeutic botanical, cannabis is legal or decriminalized throughout many 
countries in the world such as Portugal, Israel, Spain, the Netherlands and, as of 2006, 
throughout Canada (Spain; Netherlands; Canada). In countries such as Finland, Iran, Egypt and 
Cambodia, it continues to be embraced as a food or nutritional supplement (Callaway 66). From 
1850 to 1937 cannabis had been readily available in the United States as a staple in American 
medical practice for a multitude of medical conditions, as well as a widely cultivated plant fiber 
known as hemp.  It acquired its legal “taboo” after a well-funded political and economic battle 
beginning in the early twentieth century.  Against the advice of the American Medical 
Association and testimony presented by Dr. William C. Woodward, explaining that no scientific 
proof or evidence had ever been submitted to justify the claims brought against its use, the 
federal government condemned cannabis (Ben Amar 3). 
The resulting legislation made the possession, use, distribution or sale of marijuana 
illegal in the United States. Since then the federal government maintains a strict unyielding 
stance regarding the regulation and scheduling of marijuana as a controlled substance (Garvey 
2). Advocates of medical marijuana have turned to their states to enact laws that would allow 
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therapeutic access to botanical marijuana in a legal and regulated manner; generally in those 
states for which medical legalization has been sought, these advocates sustained success (Eddy 
8).   
While still illegal under federal law, as of 2012, eighteen states have approved cannabis 
for medical use: California, Oregon, Alaska, Washington, Maine, Hawaii, Colorado, Nevada, 
Maryland, Vermont, Montana, Rhode Island, New Mexico, Michigan, New Jersey, Arizona, 
Delaware, Connecticut, as well as the District of Columbia. Although not enacted in the same 
manner, nor equivalent from state to state, all legislation is based on a form of compassionate 
medical use of cannabis for various medical conditions, including, but not limited to glaucoma, 
cancer, AIDS, multiple sclerosis, Crohn’s Disease, anorexia, neurological disorders, and pain 
management (Ben Amar 6).   
Since scientists isolated its main active ingredient, δ-9-tetrahydrocannabinol in 1964, 
further medical research, conducted by a variety of medical centers around the world, from Haifa 
University in Israel to the University of Arkansas in the United States, continue to present 
evidence regarding the medical efficacy of cannabis. Discovered in the 1990s, the 
‘endocannabinoid’ or human cannabinoid system would prove to be responsible for modulating a 
vast range of physiologic systems from the central nervous system to the immune system. Its 
interaction with cannabis resulted in the wide range of therapeutic responses found beneficial for 
a variety of diseases or illness (Ben Amar 6).  
Equipped with this information, the legal framework to support their endeavors, and the 
bio-chemical expertise of enterprising botanical experts, many savvy chefs have ventured into a 
new culinary frontier: the development of medical marijuana edibles.  Although the commonly 
known method of ingesting cannabis is through inhalation, many individuals would prefer to 
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acquire their medicinal cannabis by edible ingestion (Vinson). Due to the creative culinary 
talents of many chefs and the unique, delicious products they are developing, the edibles market 
is growing. 
 The next chapter will review the scholarly literature on the etymology and history of 
cannabis, now commonly known as marijuana. It will also describe in greater detail the legal 
hurdles marijuana advocates encountered and continue to struggle with in the United States, as 
well as peer reviewed medical research that continues to support and uncover further evidence of 
cannabis’ medicinal, therapeutic value. Included will be an analysis of the active and effective 
therapeutic ingredients in cannabis; how they are extracted, evaluated and concentrated for 
edible use, as well as the current parameters regarding the cultivation and dispensation of 
cannabis. Of the eighteen states previously noted that legalized cannabis for medical use, four 
will be presented in detail regarding the enactment of legalization policies, medical uses defined 
by those policies, established cultivation restrictions and standards, as well as distribution 
requirements.  
Chapter Three discusses the development of the edible frontier, exploring cultivation 
methods, quality control and dosing parameters, as well as the growth of the medical marijuana 
edible market within these four states, while introducing chefs who are creatively engaged in 
producing unique products using cannabis.   A detailed explanation of cultivation practices 
employed by each establishment, their use of biochemical evaluation standards, the 
determination of each product’s dose, and the development of these products will be provided. 
This explanation includes which products are dispensed and the methods by which they are 
dispensed.  
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Chapter Four covers the results of two surveys: one provided to the chefs, retailers and 
vendors of edible products; the other provided to the authorized patients. This data will be 
evaluated and used to illustrate the growth of the medical edible market, as well as its value to 
patients, to prove enterprising chefs within this market produce products the authorized patient 
base desires, demonstrating and supporting the conclusion in chapter five that the medical 
marijuana edible market is truly a new, viable culinary frontier. 
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Chapter Two 
Cannabis: A Progression of Perspective 
Etymology 
 
“Cannabis” has a varied etymological derivation. The whole class of names is held to 
have originated in the Persian kanab (Dymock et. al.).  Of the various terms associated with the 
cannabis plant, marijuana is one of the most universally recognized, yet its origins remain deeply 
obscure. There are a wide variety of Chinese terms that refer to cannabis and cannabis products 
(Piper 4). The closest approximation of Chinese terms that refer to cannabis would be ma ren 
hua which means “hemp seed flowers.”  “The root of the word marijuana might be a Semetic 
loan word in Spanish, having an Arabic origin, later being imported to Mexico from Moorish 
Spain” (5). The term “marijuana” was virtually unknown in the English language until 
approximately 1936, when William Randolph Hearst introduced it as “the killer weed from 
Mexico” in his well-funded, journalistic campaign to denigrate and destroy hemp production in 
the United States (French 129). Today, the term “marijuana,” whose spelling has been adapted 
from the Spanish slang marihuana invokes a variety of perspectives (129). Depending on an 
individual’s understanding and education, marijuana may be associated with the “War on 
Drugs;” it may be an integral component of religious practice or cultural expression, it may be a 
source of fiber, it may represent a source of nutritional value or it may be consumed for 
medicinal purposes (Callaway 66). All of these interpretations create an aura of mystery and help 
to stoke the controversy surrounding the use of medical marijuana.  
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History 
 
  Cannabis was cultivated and consumed long before written historical record. Since the 
Neolithic period in northern China, around 4000 BC, research indicates this ancient plant had a 
vast array of uses (Ben Amar 2). “Besides its importance as a fiber plant, it was also an important 
food plant, one of the major “grains” of the ancients. And it was an important medicinal plant” 
(Li 437).  According to Li, Emperor of China, Shen Nung, first described the properties and 
therapeutic uses of cannabis in his compendium of Chinese medicinal herbs, published in 2737 
BC . By 2000 BC, cannabis, or bhang, was cultivated in India, described as one of the five 
sacred plants, according to The Vedas.  Trade along the Silk Road introduced cannabis to many 
cultures (438). During the Middle Ages soldiers would acceptably and commonly drink bhang 
before going into battle, just as Westerners would drink swigs of whisky (Gumbiner).  The 
medieval physician Avicenna included it in his formulary, and Europeans of the same epoch ate 
its nutritional seeds and made its fibers into paper, a practice that continued for centuries (Ben 
Amar 2). Early in history, observations were made regarding the types or qualities of different 
cannabis plants. From 1785 through 1849 several individuals were involved in determining or 
differentiating the strains of this plant to discover an explanation for the physical difference 
between each plant as well as the difference of the medicinal effects of each plant. Indica 
dominant strains are short, dense plants with broad leaves and often grow a darker green. Sativa 
dominant strains are tall, thin plants with narrow leaves and grow a lighter green in color (Hillig 
and Mahlberg 970; Appendix E). The scientific community attributes the work of Jean-Baptiste 
Lamarck, in 1785, as the first to differentiate C. Indica from C. Sativa (968).  
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Further scientific discoveries were made during the British colonization of India. While 
working as a British physician and surgeon in India, William O’Shaughnessy discovered the 
medicinal attributes of cannabis.  He conducted the first comprehensive clinical trials about 
cannabis therapy and published his work in 1839.  Before his publication, little was known about 
cannabis in Europe and America. After O’Shaughnessy’s publication, cannabis was available in 
extract and tincture form. It was listed in the British Pharmacopoeia for the next one hundred 
years (Aldrich).   
Between 1850 and 1937 cannabis was used in American medical practice for a multitude 
of medical conditions. It was admitted to the United States Pharmacopeia as a recognized 
medicine in 1850 under the name Extractum Cannabis or Extract of Hemp (The Pharmacopoeia 
of the United States of America 332). The National Formulary and United States Dispensatory 
cited recommendations for its use in numerous illnesses (Wood and Bache 310).  Leading 
pharmaceutical companies like Brothers Smith, Eli Lilly, Parke-Davis, and Tildens produced a 
cannabis extract that was sold freely in pharmacies of western countries (Sasman 51).  In 
addition to medicinal tinctures or extracts, edible products were produced from cannabis. The 
Gunjah Wallah Company made maple sugar hashish candy starting in the 1860s, which soon 
became one of the most popular treats in America. For forty years, it was sold over the counter 
and advertised in newspapers, as well as being listed in the catalogs of Sears-Roebuck, as a 
totally harmless, delicious and fun candy (Aldrich), 
 As a fiber known as hemp, cannabis was widely cultivated in the United States for both 
paper and textile production (French 129). Until 1883, 75-90% of all paper in the world was 
made with cannabis hemp fiber, including paper for books (Herer 22). At the end of the 
nineteenth century cannabis production became overshadowed by cotton production. Canvas, a 
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word derived from the Latin term cannapaceus or ‘made of hemp,’ was the material of choice 
for sail cloth due to its ability to outlast cotton in harsh, seafaring environments. It covered the 
wagons of pioneers and old sails produced by hemp became the original Levi’s Jeans. Hemp 
seed was used extensively to produce paint and varnish; in 1935 over 116 million pounds of 
hemp seed had been consumed by this industry.  Automobile entrepreneur Henry Ford invested 
heavily in cannabis, producing an automobile that could run on hemp oil and built by panels 
made from a plastic derived from hemp, wheat and sisal fibers. The vehicle was 1000 pounds 
lighter than its counterpart made of steel and with impact strength 10 times greater than steel it 
did not dent. Despite its wide cultivation and generous market share, cannabis production 
became overshadowed by cotton production at the end of the nineteenth century (Roekel 12).  
Between1917 and 1935, the new petroleum based synthetic textile companies, as well as 
the large, powerful newspaper/lumber barons saw traditional hemp production as a threat to their 
businesses. “Nylon” had been introduced as a new synthetic fiber, and, according to 
contemporary belief, in order to succeed it had to replace the traditional hemp (French 129). 
Powerful players, such as William Randolph Hearst, Andrew Mellon, J. Edgar Hoover, and 
Harry Anslinger, spearheaded a crippling campaign against the production of cannabis. It was at 
this time the term marihuana was introduced to the American public. Unfamiliar with the term, 
Americans did not associate marihuana with cannabis or the other familiar terms used in its 
place such as ganja, hashish or hemp, and therefore did not know that marijuana was actually the 
same cannabis used in the concentrated medicines they had been taking since childhood (Herer 
32). A wide range of unsubstantiated negative claims arose against the cultivation and use of 
marijuana in the United States, stating it was responsible for violent behavior, caused insanity 
and led to immorality (37). No scientific proof or evidence was ever submitted to justify these 
Wolkowicz                       
 
                         14
claims, which were initiated and promoted through both Anslinger and Hearst through yellow 
journalism. Nor were these claims supported by the American Medical Association, as attested 
by Dr. William C. Woodward in 1937 during a meeting of the Ways and Means Committee 
under the 75th Congress of the United States (Marihuana Tax Act of 1937).  
Despite Dr. Woodward’s efforts, Congress condemned cannabis, claiming it responsible 
for “insanity, moral and intellectual deterioration, violence, and various crimes” (French 129).  
Against the advice of the American Medical Association, the United States government 
instituted the Marihuana Tax Act in 1937, whose spelling of marihuana is reflected in almost all 
federal and state laws (Eddy 2). It required that one dollar be paid as tax when an ounce of 
marijuana was used for medical purposes and that one hundred dollars be paid as tax when the 
ounce was used for “unapproved” purposes. The Marijuana Tax Act imposed reporting and 
registration requirements, as well as a tax on growers, sellers and buyers. Although it did not 
prohibit marijuana outright, the effect was the same.  Cannabis was removed from the United 
States Pharmacopoeia in 1942, losing its therapeutic legitimacy (Ben Amar 2). 
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Legal Issues 
 
The Marijuana Tax Act of 1937 heavily regulated cannabis production and distribution.  
In 1961 the Single Convention on narcotic drugs was enacted; it consolidated previous treaties 
and broadened their scope to include cannabis (United Nations). In 1969, the United States 
Supreme Court declared the Marihuana Tax Stamp Act of 1937 unconstitutional because it 
required that the person seeking a tax stamp incriminate himself, in direct violation of the Fifth 
Amendment to the U.S. Constitution (Leary v. United States). Responding to this decision, in 
July of 1969, President Nixon asked Congress to enact legislation to combat rising levels of 
recreational and abusive drug use. Cannabis was included in this legislation as a harmful drug 
and an illegal substance.  Citing ‘interstate commerce’ as the basis of their authority, the House 
and Senate filed a conference report that was adopted in both chambers as the Comprehensive 
Drug Abuse Prevention and Control Act of 1970, which was re-titled in 1971 as the Controlled 
Substances Act (CSA), specifically stating that drugs listed under this act were under federal 
jurisdiction (“Drug Abuse Prevention and Control”).  In contrast to earlier acts, this one was to 
control drugs directly, not through taxation, moving enforcement out of the Treasury to the 
Justice department. This act made the possession, use and sale of marijuana illegal and 
established the Drug Enforcement Agency (DEA) (Drug Enforcement Administration; Eddy 8).  
The Attorney General became responsible for enforcement, but the department of Health, 
Education and Welfare, now known as the Department of Health and Human Services, through 
the FDA are in charge of defining what needs to be controlled considering these crucial points:  
1. Pharmacologic actions; 2. Other scientific knowledge about the drug in question and other 
drugs; 3. Risk to public health; 4. Dependence, referring to psychic or physiological, potential; 
and 5. Whether the drug in question acted as a precursor for other drugs listed. Alcohol, caffeine 
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and tobacco were excluded from the list (USA: Department of Health and Human Services). 
Cannabis, or marijuana, was discussed separately and treated differently than the other drugs 
noted within this act, which called for the creation of a separate commission to study cannabis 
and report back with its findings in 1972.  The results of this commission’s study recommended 
that cannabis be downgraded to a misdemeanor (Sloman 344).   
During the 1970s, the Carter administration worked toward legalizing cannabis and asked 
Congress to abolish federal criminal penalties for individuals possessing less than one ounce 
(Carter). Since then, various bodies of the federal government retain their resolute, unyielding 
stance regarding the regulation and scheduling of marijuana as a controlled substance (Eddy 18). 
Despite the federal government’s unwillingness to objectively review the medical use of 
marijuana, the Obama Administration Department of Justice, in October 2009, announced an end 
to federal raids by the Drug Enforcement Administration of medical marijuana dispensaries that 
are operating in “clear and unambiguous compliance with existing state laws.” (Johnston and 
Neil A. Lewis A20; United States of America Department of Health and Human Services).   
Currently, medical marijuana advocates have been successful in changing state laws to 
decriminalize cannabis for medicinal purposes in eighteen states and the District of Columbia 
(Eddy 8). As a result, individuals who have received a recommendation for its use by a medical 
doctor will not be subject to state-level prosecution for the cultivation, possession, and use of 
marijuana. Additionally, physicians in these states are immune from liability and prosecution for 
discussing or recommending medical cannabis to their patients in accordance with state law. In 
all of these states, programs to regulate the use of medical marijuana are in place or are 
developing. With the exception of New Mexico and New Jersey, patients in state programs may 
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be assisted by individuals known as caregivers, who are authorized to help patients grow, acquire 
and use marijuana (18).  
Marijuana was first approved for medical use in California in1996; followed by Oregon, 
Alaska, Washington, and the District of Columbia in 1998; by Maine in 1999; Hawaii, Colorado, 
and Nevada in 2000; Maryland in 2003; Vermont and Montana in 2004; Rhode Island in 2006; 
New Mexico in 2007; Michigan in 2008; New Jersey and Arizona in 2010; Delaware in 2011; 
and Connecticut in 2012 (Eddy 20).  Not all legislation has been enacted in the same manner nor 
is it equivalent from state to state. Each state has different regulations regarding the cultivation 
and dispensing of medical marijuana. Due to the scope of this project and the data acquired on 
the marijuana edibles market, this thesis compares legal, medicinal, cultivation, and dispensary 
parameters regarding cannabis in four states: California, Colorado, New Mexico and Rhode 
Island.  
California 
 
 
 The first state to legalize marijuana for medical purposes, California, adopted Proposition 
215 of November 6 of 1996 as California Health and Safety Code 11362.5. Called the 
Compassionate Use Act, it legalized cannabis for “the treatment of cancer, anorexia, AIDS, 
chronic pain, spasticity, glaucoma, arthritis, migraine, or any other illness for which marijuana 
provides relief.” Proposition 215 removed the state’s criminal penalties for medical marijuana 
use, possession, and cultivation by patients with the “written or oral recommendation or approval 
of a California licensed physician” who has determined that the patient’s “health would benefit 
from medical marijuana.” Possession of marijuana in an amount sufficient for the patient’s 
“personal medical purposes” is legal. Approved in 2003, Senate bill 420 went into effect on 
January 1, 2004, as California Health and Safety Code 11362-83.  This legislation broadened 
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Proposition 215 to transportation within the state, allowing patients to form medical “collectives” 
or “cooperatives” for growing marijuana and “reasonable compensation” for medical marijuana 
caregivers, stating that the drug should be distributed on a non-profit basis. Caregivers were 
initially defined as the individuals designated by the qualified patient, who has consistently 
assumed responsibility for the housing, health, or safety of that patient. This designation has 
been expanded to include an individual or business, which assists a dispensary in processing or 
preparing edible medical marijuana products. This legislation empowers California localities to 
adopt scientific medical marijuana guidelines, which support individual dispensaries to promote 
product standards from within the industry to demonstrate their dedication to providing their 
patient base with quality medical edible products (Cal Health & Safety Code 
Ann.§11362.765(b)(3)). It also established a voluntary state identification card system run 
through county health departments (Cal Health & Safety Code Ann. §11362.5 and §§11363.7 to 
11363.83).  
 Specific dispensary regulations were also enacted, creating a state-wide template for the 
legal distribution of medical marijuana to all counties. A “Medical Marijuana Storefront 
Collective Dispensary Permit Application” was created to define the parameters for the location 
and operation of all dispensaries. In accordance with these regulations, individuals could 
consume edible products within the dispensary but not smoke or inhale marijuana products. A 
default limit has been set, stating that a qualified caregiver or patient can maintain no more than 
eight ounces of dried mature flowers of budding female cannabis plants or the plant conversion 
plus six mature plants or 12 immature plants. A physician is able to grant an exemption for 
quantities if medical need is determined. If grown in “cooperatives” or “collectives,” a cultivar of 
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up to 100 plants is within legal limits. Notice shall be clearly posted within the dispensary stating 
that marijuana shall not be smoked, ingested or consumed on the premises.  
Colorado 
 
 
 On November 7, 2000, the state legislature enacted Colorado’s Medical Marijuana Law. 
Colorado voters approved Amendment 20, adding Section 14 to Article 18 of the Colorado 
Constitution (Colo. Const., Art XVIII §14). Similar to California’s Proposition 215, Colorado’s 
law legalized cannabis for the treatment of “debilitating medical conditions” including but not 
limited to “cancer, glaucoma, positive states for human immunodeficiency syndrome, or AIDS, 
seizures, severe muscle spasms, MS” or “any other medical condition” approved by a physician. 
It also excludes individuals from state prosecution for “acquisition, possession, production, use, 
or transportation of (medical) marijuana or paraphernalia” with the approval or recommendation 
from a state licensed physician (Colo Const. Art XVIII §14).  
As of June 1, 2001 the state health agency created and continues to maintain a 
confidential registry of patients who are entitled to receive a registry identification card.  Unlike 
California, each patient or caregiver seeking legal state access to medical marijuana must apply 
for and carry a state registry identification card.  Legal possession of this card excludes those 
individuals from state criminal penalties for engaging or assisting in the use of medical 
marijuana. This regulatory process, by being stricter than that of California, and preventing 
anonymity, may limit the number of qualified individuals’ access to medical marijuana. It may 
also help to track the growing number of medically authorized patients allowing Colorado to 
license enough dispensaries for patients in need. The Colorado Medical Marijuana Code, C.R.S. 
§ 12-43.3-101, et seq., clarifies Colorado law regarding the scope and extent of Amendment 20 
to the Colorado Constitution. At the same time it authorizes a mechanism for the retail sale, 
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distribution, cultivation and dispensing of medical marijuana known as a "Medical Marijuana 
Center." It further authorizes licensing mechanisms known as an "Optional Premises 
Cultivation” and a “Medical Marijuana-Infused Products Manufacturers’ License.”  A permittee 
may not dispense more than two ounces of a usable form of medical marijuana, or in the 
alternative, six marijuana plants, three or fewer of which may be mature flowering plants per 
patient, per day.  Sales tax is due on all products sold at dispensaries (United States of America, 
Legislative Council).  
New Mexico 
 
 
 On April 2, 2007, the Lynn and Erin Compassionate Care Act (Senate Bill 523) went 
into effect in New Mexico.  It also was enacted to allow use of medical cannabis for “alleviating 
symptoms caused by debilitating medical conditions and their medical treatments” including but 
not limited to “cancer, glaucoma, multiple sclerosis, AIDS, neurological disorders and any other 
medical condition, medical treatment or disease approved by the department of health.” The 
number of qualified medical conditions continues to expand, including PTSD and Crohn’s 
disease (N.M. Stat. Ann.§26-2B-1). Individuals who are residents of the state receive approval 
form a state licensed physician for medical marijuana use, and who carry a registry identification 
card will not be prosecuted for the possession of up to an “adequate amount” or what would be 
the equivalent of a three month’s supply of medical marijuana, which is six ounces. A qualified 
caregiver would also receive a registry identification card and would receive the same legal 
protection from prosecution if in possession of up to an adequate amount of medical marijuana. 
It is not legal for caregivers to use medical cannabis unless they are certified patients themselves. 
(N.M. Stat. Ann. §26-2B-3(F).  Unlike most other state programs, patients and their caregivers 
cannot grow their own marijuana; rather, it must be provided by state-licensed “cannabis 
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production facilities.” In New Mexico there is a process by which “a person or an association of 
persons” can be determined by the department of health to be qualified and licensed to “produce, 
possess, distribute, and dispense cannabis.” These individuals will also not be subject to 
prosecution, in any manner, for the possession, production, distribution or dispensation of 
cannabis. As of July 10, 2012 twenty-three of these licensed production facilities are operating. 
In December 2010 New Mexico revised regulations increasing the number of plants these 
non-profit facilities could grow from 95 to 150. The updated regulations also allow licensed 
producers to obtain plants, seeds, and/or usable cannabis from other non-profit producers.  On 
March 5, 2012 the residing governor of New Mexico signed Senate Bill 240, creating a medical 
cannabis fund to cover the program’s costs.  As of August 29, 2011 3,981 New Mexico residents 
were registered to benefit from medical marijuana treatments, by October 2011, the latest period 
for which the health department has statistics, 4,310 patients were registered to receive medical 
marijuana (Sundberg).  
Rhode Island 
 
 
 On January 3, 2006 The Edward O. Hawkins and Thomas C. Slater Medical Marijuana 
Act took effect in Rhode Island. The law removes state-level criminal penalties on the use, 
possession and cultivation of marijuana by patients who possess “written certification" from their 
physician stating, "In the practitioner's professional opinion, the potential benefits of the medical 
use of marijuana would likely outweigh the health risks for the qualifying patient.”  The illnesses 
given legal protection under this act include but are not limited to: “cachexia; cancer; glaucoma; 
Hepatitis C; severe, debilitating, chronic pain; severe nausea; multiple sclerosis and Crohn's 
Disease.”  Other conditions may be approved by the Rhode Island Department of 
Health.  Caregivers must be at least 21 years old and can only manage up to five patients at any 
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time. Both patients and/or their primary caregivers may legally possess 2.5 ounces of cannabis 
and/or 12 plants. All plants must be stored in an indoor facility. The law establishes a mandatory, 
confidential state-run patient registry that issues identification cards to qualifying patients. In 
2009, Rhode Island lawmakers enacted legislation authorizing the establishment of state-licensed 
not-for-profit “compassion centers” to “acquire, possess, cultivate, manufacture, deliver, transfer, 
transport, supply or dispense marijuana, or related supplies and educational materials, to 
registered qualifying patients and their registered primary caregivers,” to be overseen by 
the State Department of Health (Rhode Island Department of Health).   
On May 22, 2012, despite his previous October 2011 decision to invoke an indefinite 
licensing suspension of compassion centers, based on concerns that the number of plants grown 
by compassion centers might be mistaken for commercial enterprises by the DEA, Governor 
Lincoln Chafee signed into law Senate Bill 2555. Under the new law health regulators will 
license three not-for-profit entities to operate within the state, still deemed as 'compassion 
centers’.   The Department of Health named Greenleaf Compassionate Care Center in 
Portsmouth, Summit Medical Compassion Center in Warwick, and The Thomas C. Slater 
Compassion Center off Smithfield Avenue in Providence as the beneficiaries for licensure. These 
centers are legally certified to produce and distribute medical marijuana to authorized patients. 
Similar to the New Mexico law, these compassion centers will not be allowed to cultivate more 
than 150 cannabis plants on the premises at any one time, only 99 of which may be mature. The 
centers will also be restricted to possessing no more than 1,500 ounces of usable product at any 
one time (Senate Bill 2555).  These statutory limitations were crafted so as to minimize the 
likelihood of federal intervention with the state’s law implementation. Currently over 4,400 
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Rhode Island residents are legally authorized to use cannabis medically (Rhode Island 
Department of Health). 
In each of these states, the medical edible market grew out of a compassionate concern to 
patient access to medical marijuana that did not require ingestion through smoking. Individual 
chefs, themselves patients, creatively approached the process of developing delicious edible 
products capable of providing patients with adequate doses of medicinal cannabis. Committed to 
working within the legal guidelines of each of their respective states, these chefs investigated 
methods of extracting the medicinal components from the cannabis plant.  They recognize their 
market is limited by the regulations imposed by their state, as well as the limitations imposed on 
them by federal regulations. State laws clearly limit sales; products cannot be sold across state 
lines to comply with the Interstate Commerce Act. Cultivars cannot exceed the number of plants 
defined by each state’s regulation and should be maintained in those numbers so not to be 
interpreted by federal officials as commercial enterprises.  According to the stance of the Obama 
administration, the risk to this market may be increasingly minimized as long as each 
establishment is careful to comply with its respective state laws.  
To prove state compliance and to minimize risk of federal prosecution, dispensaries must 
provide visible state registration documentation. All dispensaries must provide documentation of 
what products are sold and the amount of products sold. The dispensation of cannabis must be 
clearly designated for medicinal purposes and for state recognized illnesses or disease. Patients 
are also required to present documentation to demonstrate they are authorized to use medical 
marijuana. Many states use their health departments or health agencies to monitor the cultivation 
and use of medical marijuana. Sometimes, it can be more efficient for states to employ the 
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support of local agencies to oversee and collate the data affiliated with the medical distribution 
of cannabis (Eddy 17).  
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Medical Issues 
 
Over the past five decades marijuana has begun to regain support within the medical 
community (Pertwee S163). Experimenting with O’Shaughnessy’s recipes, from 1850 to 1964 
chemists struggled to identify and isolate the active components of cannabis. Its main active 
ingredient, δ-9-tetrahydrocannabinol (THC), was not isolated until 1964, and not until the 1990s 
was the human cannabinoid system discovered (Gaoni et. al. 1646; Bostwick 176; Kogan and R. 
Mechoulam 423).   This “endocannabinoid” system would prove to be spread throughout the 
human body, regulated by receptors, identified as CB1 and CB2, which were responsible for a 
vast range of modulatory activities.   In 1992 William Devane and Raphael Mechoulam 
identified an endogenous brain molecule, naming it ‘anandamide’ from the Sanskrit word for 
“eternal bliss”.  Anandamide is an endocannabinoid, a neurotransmitter that binds to and 
activates the cannabinoid receptors (423).  THC, also a cannabinoid, is technically known as a 
plant derived or phytocannabinoids and mimics the actions of anandamide, meaning that THC 
also binds with the cannabinoid receptors (423). Physiologically, these receptors are instrumental 
in modulating the central nervous system, the autonomic nervous system, the immune system, 
the gastrointestinal tract, the reproductive system, the cardiovascular system and the endocrine 
system (Bostwick 178; Kogan 425). They influence a vast array of functions as diverse as the 
regulation of food intake, visceral sensation, gastrointestinal motility, intestinal inflammation 
and cell proliferation.  Systemic endocannabinoid interaction with external cannabinoids, 
cannabidiol and THC of cannabis produces anti-anxiety, anti-psychotic, anti-convulsive, 
antiemetic, and anti-inflammatory effects, as well as pain relief, and appetite stimulation 
(Bostwick 172).  Research studies are showing evidence of suppressed neoplastic tumor growth 
associated with cannabis use, including decreased angiogenesis, decreased metastasis through 
Wolkowicz                       
 
                         26
interference with cell migration, inhibited carcinogenesis, and attenuated inflammation 
(Bostwick 178; Morgan and Lyn Zimmer 2; Baker et. al. 85).  Significant evidence demonstrates 
that cannabis or marijuana is medically effective when used to treat a myriad of conditions 
including glaucoma, cancer, AIDS, muscle spasms, anorexia, chronic pain, neurological 
disorders, severe nausea, anxiety, insomnia, tremors, post-traumatic stress disorder (PTSD), and 
to reduce tumor size (Baker et. al. 83; Ben Amar 4; Aggarwal et. al 52; Ganon-Elazar and Irit 
Akirav 458). A study published in the June 2012 edition of the Journal of Clinical Cardiology 
states studies so far show a promising effect of modulation of the cannabinoid system on 
myocardial injury. CBD in conjunction with both CB1 and CB2 reduced infarct size, leading to a 
preservation of ejection fraction or heart function. Systemic cannabinoid interaction with CB1 
and CB2 receptors, by a non-inhalation route via oral ingestion, may provide a more effective 
therapy for altering the course and complications of atherosclerosis (Singla et. al. 335). 
Scientific, medical inquiry continues to further understand and determine the specific medicinal 
benefits of each cannabinoid at universities such as Haifa University, Israel; UCLA, United 
States; and the University of Arkansas, United States. 
Over eighty cannabinoids have been identified in the cannabis plant. Further research has 
helped to elucidate these cannabinoids and their medicinal attributes. The major active 
cannabinoids include: tetryhydrocannabinol (THC), tetrahydrocannibinolic acid (THCA), 
cannabidiol (CBD), cannabidiolic acid (CBDA), cannabinol (CBN), cannabigerol (CBG), 
tetrahydrocannabivarin (THCV), and cannabichromene (CBC).  THC, the most abundant 
cannabinoid in cannabis, it has mild analgesic effects and can act as an antioxidant. THC also 
creates the psychoactive therapeutic effects of cannabis.  THCA, which is the most prevalent 
cannabinoid, includes many anti-inflammatory, anti-proliferative, and anti-spasmodic properties, 
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which have numerous applications in medicine, such as inhibiting cell growth in tumors or 
controlling muscle spasms in patients with multiple sclerosis. CBD, in repeated studies, has been 
determined to exhibit a profound number of therapeutic effects acting as an antipsychotic, anti-
epileptic, neuroprotective, vasorelaxant, antispasmodic, anti-ischemic, anti-proliferative, 
antiemetic, antibacterial, antipsoriatic, intestinal anti-prokinetic, analgesic, bone stimulant, and 
anti-inflammatory (Bostwick 172). CBDA, similar to THCA, is the main constituent in cannabis 
that has elevated CBD levels.  THCA and CBDA hold most of the anti-inflammatory properties 
that cannabis has to offer.  CBN occurs when the plant material is old or has degraded and 
suppresses or eliminates the psychoactive benefits of TCH.  CBG exhibits antibacterial effects 
and has been shown to relieve intraocular pressure, especially useful in the treatment of 
glaucoma. THCV is a homologue of THC, it has been found to include properties for metabolic 
disorders, for example, lowing blood sugar levels for use in diseases such as Type II 
diabetes.  When used in conjunction with CBDA, THCV could help treat prostate cancer. CBC is 
also useful for its anti-inflammatory and anti-viral effects (SC Labs). 
The two cannabis family species, C. sativa and C. indica, have been found to differ in 
medicinal properties. C. Sativa strains have higher concentrations of δ-9-THC and lower levels 
of CBD.  C. Indica strains have moderate levels of δ-9-THC and increased levels of CBD. Sativa 
produces a more euphoric therapeutic effect, relieving stress and effectively aiding with 
depression. It has been proven as a treatment for glaucoma, reducing intraocular pressure. Indica 
provides full body pain relief and is extremely effective in relieving pain endured by patients 
undergoing chemotherapy. Individuals fighting AIDS also experience relief from chronic pain. 
Both cancer and AIDS patients demonstrate increased appetite with the support of C. indica. It is 
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proven to be beneficial for those dealing with insomnia and multiple sclerosis (Golden State 
Collective).  
The arguments against the medical use of cannabis include concerns about addiction, 
over-dose, and, if inhaled, the negative effects on the respiratory system and on pulmonary 
function (Bostwick 178). The lifetime dependence risk of cannabis is 9% versus 32% for 
nicotine, 23% for heroin, 17% for cocaine, and 15% for alcohol.  The risk of new-onset 
dependence on cannabis is essentially zero after the age of 25 years, on cocaine new-onset 
dependence grows until the age of 45 years, and alcohol users will keep on making the transition 
from social use to dependence for decades after their first use. (178; Wagner and JC Anthony 
484) 
Although effectively developed to relieve pain and treat other medical conditions, the 
medications which hastened the decline of cannabis’ use in medicine, such as aspirin, morphine 
and other opium-derived drugs, also produce negative side effects (Zimmerman et. al.). 
Traditionally, medical professionals prescribe potentially dangerous and addictive painkillers, 
such as oxycodone, vicodin, morphine, Demerol, and codeine to patients for treatment of the 
same conditions (Dhalla, I. A. et. al. 893; SAMHSA).  Many of these medications are not only 
associated with unpleasant side effects from chronic use, they are also frequently associated with 
overdose, abusive and illegal use (SAMHSA). Due to the near absence of CB1 receptors in the 
brainstem, the autonomic nervous system is spared from the fatal respiratory outcomes 
associated with opioids and other traditional painkillers, with the result that no lethal overdose of 
cannabis in humans has ever been reported (SAMSA; Bostwick 180; Canada). 
            If inhaled, medical marijuana does pose respiratory risks, which have been reported 
(Bostwick 179). A marijuana cigarette is more harmful to health than oral THC. In theory, it can 
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cause as many pulmonary problems as 4-10 regular cigarettes (Kleber et al. 100). Some studies 
indicate cannabis smokers are at greater long-term risk of suffering from pharyngitis, rhinitis, 
asthma, bronchitis, emphysema and lung cancer (van Hoozen and Carroll Cross 254; Hall and N. 
Solowij 1613). In their review of the scientific evidence, John P. Morgan and Lynn Zimmer state 
that moderate smoking of cannabis appears to pose minimal danger to the lungs (Canada). There 
have been no reports of lung cancer related solely to cannabis. However, because researchers 
have found precancerous changes in cells taken from the lungs of heavy cannabis smokers, 
the possibility of lung cancer from cannabis cannot be ruled out. Unlike heavy tobacco smokers, 
heavy cannabis smokers exhibit no obstruction of the lung's small airways, indicating that 
emphysema might not develop from smoking cannabis (Canada). Researchers at UCLA report 
"marijuana smokers probably will not develop emphysema.” A recent study of 268 cannabis 
smokers in Australia supports the UCLA finding. After smoking cannabis on a daily or weekly 
basis for an average of nineteen years, the cannabis users had a lower prevalence of emphysema 
and asthma than the general population (Hashibe et. al. 1829; Swift et. al. 190). Another study 
conducted at the Kaiser-Permanente HMO, funded by the NIDA, followed 65,000 patients for 
nearly a decade, comparing cancer rates among non-smokers, tobacco smokers, and marijuana 
smokers.  Tobacco smokers had massively higher rates of lung cancer and other cancers. 
Marijuana smokers who did not also use tobacco had no increase in risk of tobacco-related 
cancers or of cancer risk overall.  Their actual rate of lung and most other cancers were slightly 
less than that of non-smokers, though the difference did not reach statistical significance (Sidney 
et. al. 722). In May of 2006 Tashkin completed an additional control study comparing 1200 
patients with lung, head and neck cancers to a matched group with no cancer.  Even the heaviest 
marijuana smokers had no increased risk of cancer, and had somewhat lower cancer risk than 
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non-smokers.  Tobacco smokers demonstrated a 20-fold increased lung cancer risk (Hashibe et. 
al. 1829). On average, Marijuana smokers do not smoke as frequently or heavily as those noted 
in the UCLA studies.  This data and continuing research helps to elucidate the risks posed to 
those who choose to smoke cannabis for medical purposes.  This consideration is less important 
in the case of palliative care provided to terminally ill patients. 
Although smoke inhalation has been the preferred method for accessing the medicinal 
effects of marijuana, many patients find inhalation noxious and compromising if they are 
suffering from respiratory conditions.  Ohlsson and Lindgren investigated the efficacy of orally 
ingesting cannabis in 1980 (Lindgren et. al. 409).  To be effective medicinally the plant material 
must be heated to decarboxylate or transform the inactive tetrahydrocannibinolidic acids into δ-
9-tetrahydrocannabinol (Canada; Grotenhermen, “Clinical Pharmokinetics of Cannabis” 
13).  Heating for five minutes at 200˚-210˚C is optimal for this conversion. Potency and 
medicinal efficacy of cannabis products is significantly increased by cooking or baking the 
material (Grotenhermen 4).   
Cannabinoids are soluble in lipids or alcohol not water, therefore any 
medicinally effective transformation of the cannabis plant into edible form must include infusion 
into fats or alcohol with heat. Most edible products produced using cannabis include fats such as 
butters or oils infused with cannabis. According to Gottlieb, when properly prepared edibles are 
a more efficient means to absorb cannabinoids (Gottlieb 8). Once eaten, absorption by the 
gastrointestinal tract is quite effective, relatively slow and noticeably different from that 
of smoking.  Onset of the medicinal effect is slower and lasts longer at lower plasma THC 
concentrations (Lindgren et. al. 411). After absorption through the gastrointestinal tract, THC 
passes through the liver and is metabolized into 11-OH-THC (11-hydroxy-tetrahydrocannibinol) 
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which is four to five times more potent than δ-9-THC (Aggarwal et. al. 52; Lemberger et. al. 
685). This effect is realized by the patient because the metabolite 11-OH-THC is almost bound 
completely to protein in the plasma, can cross the blood brain barrier with ease, and is eliminated 
only slowly from lipid containing tissue, which provides the patient with a more consistent, 
steady medicinal effect.  The medicinal onset is gradual, usually taking forty minutes to one 
hour, it then continually increases in effectiveness to plateau for 4-6 hours, ultimately providing 
medicinal benefit for 6-8 hours (Appendix C, Medical Chart 3; Medical Chart 2). Unlike smoked 
cannabis, patients avoid the “rush” caused by de-oxygenation of the blood combined with a 
short-term rise in blood pressure and heart rate (Adams 1585; Lindgren et. al. 412). 
 Pragmatically, patients choosing to use edible cannabis products experience a more 
consistent medicinal effect, that does not require repeat dosing throughout the day or night. Long 
exposure in the stomach may decrease the potency of oral cannabis for example, if taken with 
meals that are difficult to digest.  Therefore, for the maximal medicinal effect, edible products 
produced with cannabis may be best taken with a light meal or thirty to forty minutes before 
consuming a heavy meal. Additionally, if illnesses occur during pregnancies that indicate 
medicinal benefit from cannabis, cannabis in edible form is less toxic to the fetus than when 
inhaled. The 11-OH-THC metabolites cross the placenta less efficiently than THC.  When taken 
orally, the fetal plasma concentrations of THC are approximately only one-tenth the maternal 
THC concentration as opposed to fetal plasma levels that are approximately one-third maternal 
THC concentrations when cannabis is inhaled (Grotenhermen, “Clinical Pharmokinetics of 
Cannabis” 30; Huestis 33). 
Much of the data regarding the effectiveness and absorption of orally ingesting cannabis 
is cited from studies conducted in the 1970’s to 1980’s.  With advances in scientific laboratory 
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testing, dose concentration calculations, and product development, further research can lead to 
more accurate data to determine effective dose administration with medical edible products. 
These applications in conjunction with scientific medical research may provide more effective, 
targeted medical benefits for the patient community. 
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Chapter Three 
Development of the Edible Frontier 
 
Cultivation, Quality Control and Dosage 
 
In addition to the laws governing the dispensing of medical marijuana, cultivation, 
quality control and prescribing the correct dosage of marijuana play an important role in the 
effective use of this product.  Each individual state that has legalized marijuana for medicinal use 
has established specific guidelines for the cultivation of this therapeutic botanical. Laboratories 
run by qualified scientists or biochemists are available in many of these states to help control the 
quality as well as help establish products containing reliable medicinal doses. This section will 
address the cultivation, quality control and dosage parameters established by the following 
states: California, Colorado, New Mexico and Rhode Island. 
Cultivation 
 
The ways that a dispensary, patient, or caregiver grows their product can affect the taste 
and the dosage of the final medication. Cultivation means the process by which a person 
promotes the germination and growth of a seed to a mature marijuana plant (Rocky Ford). Many 
dispensaries or growers have chosen to cultivate plants without the use of pesticides and have 
embraced organic farming practices. State governments set clear standards to define how many 
plants can be cultivated.  
In California, medical marijuana can be cultivated by individual authorized patients or 
licensed dispensaries as long as a ventilation system is set up so no odors are detected off-site. 
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Any medical plants grown by a dispensary, including immature plants or seedlings, can only be 
dispensed by members of the collective to authorized patients (California, Medical Marijuana 
Storefront Collective Permit Application 9). According to state law, all dispensaries must have a 
security plan must be in place, including security alarms, video surveillance, and physical means 
of preventing anyone other than staff access to the growing area (10). The maximum height for 
plants grown in the dispensary is ten feet and all plants must be blocked from public view (20).  
Although California passed regulations allowing for the legal cultivation and dispensation 
of medical marijuana, clarifying that each authorized patient may grow up to six female, budding 
plants defined as “mature” or twelve immature plants, no standard maximum number of plants 
per dispensary has  been established by the state. Each city or locality within the state has 
established their own specific guidelines for cultivation. Inconsistencies also exist from county to 
county regarding the area allowed for cultivation and if indoor or outdoor growth is allowed. For 
example, Arcata county dispensaries are limited to using no more than 25% of their  properties 
for cultivation, not to exceed 1500 square feet. In Trinity and Tulare counties, dispensaries are 
allowed to cultivate up to 99 mature or budding female plants within 2500 square feet with 
proper zoning (California). The specific guidelines for cultivating medical marijuana within each 
county must be observed or the dispensaries could face stiff fines, federal investigation, 
imprisonment and confiscation. These guidelines include the size of the growing area, whether 
indoors or outdoors, the amount of plants in the area, and a set distance away from schools, 
churches, or youth areas. In Berkeley outdoor growing areas are limited to 10 mature female 
budding plants and 50 square feet per parcel. Otherwise within personal residences up to 24 
plants, 6 mature or 12 immature per patient for up to two patients inside or outside based on 
county (California).  
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The cultivation of medical marijuana in Colorado is carefully regulated and limited to six 
plants, three mature, three immature, per patient or caregiver or up to twelve mature plants per 
residence. Dispensary cultivars are strictly limited to growing up to six mature plants per patient 
unless authorization is granted and provided by a patient stating they are qualified to have more 
than six plants. Each plant’s weight is recorded and electronically tagged to be followed “from 
seed to sack,” in order to document all aspects of cultivation from start to final production. 
Documentation is provided to the state per request. At least seventy-percent of medical 
marijuana sold must be grown by a dispensary (United States of America 2). New state 
enforcement division mandates require high levels of security for each dispensary, including 
twenty-four hour agent-monitored video feed. Cultivars and/or dispensaries cannot be located 
within 1,000 feet of a school, church, park or any public facility designated for youth or minors. 
All cultivation can be either indoors, with proper ventilation, or outdoors, hidden from view. If 
cultivars are found non-compliant, they will be guilty of a misdemeanor and subject to a 
maximum penalty of six months imprisonment or a fine of one thousand dollars (2).  
Of the states legalizing medicinal use of marijuana, New Mexico has established some of 
the strictest cultivation requirements. Unlike other states, patients and caregivers are not allowed 
to grow their own medical marijuana and will face prosecution if found to do so. Cultivation 
must be carried out by licensed facilities. Any patient or group of patients can apply to become 
licensed growers by the state, but they must be certified before any plant can be cultivated. All 
cultivation, regardless of whether it takes place indoors, with required ventilation or outdoors, 
and hidden from view, must be at least three hundred feet from a school, church, or youth-
designated area. Deemed in New Mexico as “Cannabis Production Facilities,” dispensaries are 
only allowed to cultivate up to 150 plants at a time. If mold or the presence of any other bacteria 
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is found or suspected to be present in the product, the cultivator must send samples to the 
Department of Health for testing. Non-compliance of state regulations can result in civil 
penalties and criminal prosecution (N.M. Stat. Ann. §26-2B-1).  
Rhode Island has a cultivation limit of twelve mature plants per patient. Registered 
patients are allowed to cultivate their own plants. Compassionate care centers recently 
established by the state to cultivate and dispense medical marijuana for the benefit of authorized 
patients cannot grow more than 150 cannabis plants on the premises at any one time, only 99 of 
which may be mature. The marijuana must be grown indoors in a secure facility. Currently, there 
are three designated compassionate care centers, or dispensaries, located in Rhode Island: The 
Greenleaf Compassion Care Center, The Summit Medical Compassion Center, and The Thomas 
Slater Compassion Care Center. At this point in time, there is a moratorium on medical 
marijuana growth in these centers due to enforcement conflicts between the state and Rhode 
Island’s Attorney General. Fraudulent representation of the cultivation of marijuana for medical 
purposes will result in a fine of $500 in addition to any other penalties that may apply (Rhode 
Island Department of Health).  
Quality Control  
 
As medical marijuana continues to grow as a viable business, many dispensaries and 
growers cultivate cannabis to insure the safety and quality of the doses created from the plant. 
Although it is not required, the higher end dispensaries make sure that they have their products 
tested in laboratories. Numerous benefits are attained through testing edibles and other cannabis 
products. Qualified scientists are able to determine the quality of the cannabis and its strength, 
identifying major active cannabinoids, such as tetryhydrocannabinol (THC), cannabidiol (CBD), 
cannabinol (CBN), cannabigerol (CBG), tetrahydrocannabivarin (THCV), cannabichromene 
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(CBC), tetrahydrocannibinolic acid (THCA), and cannabidiolic acid (CBDA). As noted earlier, 
these cannabinoids all play key roles in the use of cannabis as a medication. These are only the 
main cannabinoids- there are over seventy in the cannabis plant.  Laboratories can examine how 
much of each cannabinoid is found in the plant material, which can determine how or why it is 
used by patients, much like aspirin, ibuprofen, or Tylenol (SC Laboratories; Halent Laboratories; 
CannLabs; CW Analytical).  
Through testing, dispensaries can assure patients of the quality and usefulness of a strain 
for a particular ailment (CannLabs). The percentage of Indica or Sativa in a strain will create a 
different medicinal effect for the user (Ben Amar 13). Laboratories can test the potency of the 
cannabis material to determine how to measure out correct doses for patients through the use of 
High Performance Liquid Chromatography (HPLC). HPLC is very useful in determining the 
exact amounts of cannabinoids present; the plant material can remain in its natural form and be 
analyzed without damaging any components. This is important because besides the main 
cannabinoids, there are also over 420 different compounds, including terpenes (responsible for 
aroma), flavonoids (responsible for flavor), glycoproteins, and alkaloids, among others contained 
within the plant leaves (SC Laboratories; CannLabs; Halent Laboratories). Screening for 
dangerous microbial agents, such as Aspergillus, Listeria, E. Coli, and many others, prevents 
patients from developing further health problems, guaranteeing that the product they are buying 
is safe and effective. Pesticides are also tested for, allowing patients to feel secure in knowing 
they will not be ingesting any harmful pesticides that could cause dizziness, nausea, headaches, 
or skin irritation (SC Laboratories; Halent Laboratories; CannLabs; CW Analytical). There are 
several well-known laboratories that test the cannabis used in the creation of, as well as the 
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resulting edible products such as Halent Laboratories, SC Laboratories and CW Analytical in 
California, CannLabs in Colorado, as well as Page Analytics in New Mexico.  
Located in California, CW Analytical meticulously tests products from Bhang Chocolates 
and Kiva Confections through cannabinoid profiling, chemical residue screening, and 
microbiological screening.  Cannabinoid profiling allows CW Analytical to test for the amount 
of THC, CBD, and CBN, three out of the seventy major cannabinoids present in cannabis. As the 
plant ages, CBN is created. If it is found in a large concentration, the resulting product will not 
be medicinally effective. CBD is responsible for the relaxing effects of cannabis, and THC is the 
major psychoactive cannabinoid, and it is helpful in pain relief. Cannabinoids are produced in 
glandular sections on the leaves of the plant known as trichomes. The resin extracted from the 
trichomes contains terpenes, as well as flavonoids, the components which are instrumental in 
providing different aromas and flavors to each plant. Chemical residue screening tests the 
product for pesticides, including organophosphates, carbamate, pyrethoids and pyrethins, and 
avermectins. These pesticides can be linked to a host of health problems, including asthma, eye 
and skin irritation, headaches, nausea, and vomiting. For additional product safety, CW 
Analytical Laboratories conducts microbiological screening for bacteria, coliforms, E. coli, and 
yeast or mold (CW Analytical).  
Halent Laboratories, also located in California, is used by edible producer, Auntie 
Dolores. Halent Labs also evaluates medicinal cannabis for product safety. They screen for 
pesticides, mold, fungus, and mycotoxins, to insure patients can be confident the product they are 
consuming is safe. The cannabinoids tested are THC, CBD, and CBN, as well as twelve others 
including THCV, THCA and CBDA. The medicinal cannabis product is tested for eight terpenes, 
including limonene, myrcene, alpha-pinene, linalool, and trans-caryophyllene (Halent 
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Laboratories). Each of these terpenes individually has been found to provide specific medicinal 
benefits. Products containing a higher concentration of terpenes provide greater medicinal 
benefits to the patient (Russo 1344).  
A well-known laboratory in Denver, Colorado, CannLabs, used by Dixie Elixirs & 
Edibles, promotes “Responsibility Through Testing.” CannLabs is fully licensed by the state of 
Colorado to perform third party testing of medical grade cannabis products, including creamery 
butter, cooking oils, hash, hash oils, waxes, and all edibles. CannLabs tests for CBD, THC, CBN, 
THCA, and CBDA. Eventually, they will be testing for THCV, CBG, and CBC. CannLabs uses 
high performance liquid chromatography to test all their samples, which allows the plant material 
to stay in its original form. This allows for the most accurate testing. As a leader and well-known 
lab in the medical marijuana community, CannLabs offers consulting for other laboratories as 
well as formulations for new edible products. Unique to Colorado growers at this time is the 
support of a USDA approved, certified professional horticulturalist (CPH), approved by the 
American Society for Horticulture Science (ASHS), who is also Medical Marijuana Enforcement 
Division (MMED) certified by the state.  Otoké Horticulture, LLC boasts one of only three 
hundred CPHs in the country and the only CPH to specialize in cannabis, helping Colorado 
grow-operations since early 2010 by teaching basic horticulture. Their work and research is 
being documented for the ASHS with the goal to see cannabis become a new crop for this 
organization to investigate fully (Otoké Horticulture, LLC ).  
Since testing is not mandatory in New Mexico, The Verdes Foundation relies on self-
regulating procedures to guarantee a safe, high-quality product. The owners of the Verdes 
Foundation grow their own cannabis outdoors on a farm in the eastern mountains of 
Albuquerque. They do not use pesticides and grow as organically as possible. The medical 
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marijuana that is grown is evaluated and regulated by the company to insure that it meets the 
highest possible standards. The Verdes Foundation hopes to one day test their products in a 
laboratory, but at this point in time they do not have that option (The Verdes Foundation). The 
Minerva Canna Group, also located in Albuquerque, New Mexico, grows all of their own 
cannabis indoors, using the most up to date technology and techniques to regulate their 
procedures. They grow their product 100% organic, with absolutely no pesticides or growth 
hormones (Minerva Canna Group). The Minerva Canna Group uses Page Analytics to evaluate 
and test their medical marijuana products (Briones).  
Standards in cannabis’ medical use can be put in place to insure that patients are 
receiving the same dose every time, establishing credibility and reproducibility. Testing provides 
consistency in texture, flavor and dosing. The dispensaries that trust their product to laboratories 
like CW Analytical, CannLabs, and Halent Laboratories give excellent accolades to their work.  
For example, Bhang Chocolates states, “CW helps ensure the consistency of our products.” 
Bhang notes that CW Analytical’s expertise in both food and cannabis science has been critical 
to the success of their medicinal chocolates. Reproducibility of each edible product is essential 
for success. Patients expect that every time they purchase any product, that product will always 
be of the same quality in terms of flavor, texture, and medicinal benefit.  “The CannLabs 
management team and their science division have brought great value” to Dixie Elixirs & 
Edibles. They have found CannLabs to be instrumental with respect to their formulations as well 
as with research and development for new edible products. Dixie Elixirs & Edibles finds that 
CannLabs remains committed to supporting infused product manufacturers like themselves, to 
insure each patient receives the highest quality medical marijuana in the safest and most 
consistent products possible. Currently, there are no testing facilities in Rhode Island.  
Wolkowicz                       
 
                         41
Dosage 
 
The dosage of medical marijuana is one of the most important outcomes of cultivation 
and testing. Because medical marijuana has not been standardized yet, it is difficult to determine 
what a proper dose is. Therefore, preparation of single dose edibles is recommended. Research 
has shown that a medically effective dose is equivalent to an absorbed amount of approximately 
16.3mg of THC (Carter et. al. 464). Further work has demonstrated that 2.5mg of THC taken 
twice daily results in appetite stimulation. 5mg of THC per meter squared of body surface area 
has been found to be effective for preventing nausea, vomiting and pain. Incremental increases of 
2.5mg up to a maximum of 15mg per meter squared of body surface area may be required and 
are recommended if the initial dose is ineffective. The same dose can be taken every two to four 
hours for a maximum of four to six doses per day. The maximum total dose is 15mg/meter 
squared of body surface area, four to six times daily, not to exceed 100-120mg per day (467; 
Appendix C, Donald Abrams Chart). Extensive testing has been conducted on edibles and, in 
most cases, analysis has proven that the medicine is not always uniformly or homogeneously 
distributed throughout an edible product. There is no guarantee that by consuming one half 
(50%) of the edible, one half (50%) of the medicinal components will be received. CannLabs 
specifically encourages and implores the manufacturing of single dose edible products 
(CannLabs). To comply with this research, edible producers such as Bhang Chocolates, Kiva 
Confections, Dixie Elixirs & Edibles and Auntie Dolores create single dose products. Each 
product or edible is carefully labeled to reflect the concentration of all medicinal components 
contained within. These chefs provide their patient base with a wide range of product choices, 
each formulated to contain reliable concentrations of medicinal components.  
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Patients need to be educated about the difference in the absorption rates and the timing of 
the medicinal effects when consuming edible products. Similar to being educated about the 
therapeutic dose and the side effects of prescription medication, patients need to understand that 
each person can be affected differently when consuming medical marijuana edible products. 
Liquid infused edibles, for instance, sodas, beverages or tinctures will be absorbed more rapidly 
than a product that requires more digestion. Patients are encouraged to wait from fifteen to thirty 
minutes when consuming a beverage or simple carbohydrate candy, and up to an hour when 
consuming a more complex carbohydrate, such as cookies, chocolates or brownies to experience 
any therapeutic response. Edible products can also produce a long lasting medicinal effect, which 
can last for four to six hours. Therefore, many dispensaries are careful to educate their patients 
before dispensing any edible products (RB).  
 
Product Development and Dispensaries 
 
Establishments, known as “dispensaries,” have been developed as locations that provide 
legal access for those with a doctor’s recommendation to purchase products made with medically 
approved and cultivated marijuana (Lunsford). Some dispensaries cultivate their plants, while 
others purchase plants from one or more certified growers. They then use the raw material to 
produce cannabis products.. The individuals involved with edible production have varied 
backgrounds; some are trained chefs, hailing from culinary schools such as Johnson & Wales 
University and New York City’s Institute for Culinary Education. Some have gained their 
training under the tutelage of experienced chefs, while others may have entered the market 
through the horticultural trade, health or caregiving experiences, developing their baking skills 
on the job based on trial and error. Being patients themselves, they have discovered and learned 
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that many patients do not want and, in many cases, cannot inhale or smoke their medical 
marijuana. Dedicated to their trade and their patient base, these chefs are committed to the 
process of creating delicious medically effective edibles. As a result of their commitment to 
producing quality products, as noted earlier, these individuals and the dispensaries they run use 
laboratories dedicated to overseeing and confirming that the proper concentrations of the 
medicinal product are obtained for each product produced.   
Developing the Edible Product 
 
 
There are a variety of compounds used in producing edibles; butters, oils, tinctures and 
extracts made from cannabis infusions are incorporated into edible products. Employing the 
same techniques used for thousands of years, chefs need to first extract the cannabinoids from 
the raw cannabis plant. Cannabinoids are hydrophobic, meaning they are insoluble in water. 
They are only soluble in fats or alcohol, therefore a fat, usually butter or oil, is heated and the 
plant is placed in the liquid. In order for the medical effects of cannabis to be experienced, the 
cannabis must be heated and boiled in fat or liquor (Gottlieb 4). Once the raw plant material is 
added, the mixture is then boiled and simmered for as little as one hour or up to a day. This 
process, known as infusing, extracts the flavor as well as the medicinal components from the 
cannabis plant. The longer the plant is infused, the stronger the flavor and potency of the dose. 
After the desired flavor is achieved, the mixture is strained, removing all solid plant particles 
from the liquid. The remaining liquid is then placed into a container. If it is butter, it will solidify 
again and will retain a greenish tint. Oil will remain in a liquid state and will also have a slightly 
green color (Cote).  
After infusing the cannabis, the butter, oil or whatever other fat based substance was 
infused, also known as “canna-butter,” can be employed to make a variety of edibles. The 
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amount of butter or oil used in a recipe will remain the same, but the amount does not all have to 
be canna-butter. For example, if a cookie recipe called for two pounds of butter, one pound could 
be canna-butter and the other half could be regular butter. The ratio of canna-butter to regular 
butter can be changed depending on how strong the developer wants the final product to be. 
Edibles can also be made with hash, created from marijuana resin which imparts a sweeter, 
mellower flavor (Gottlieb 8).  
Each of these prepared components are evaluated for medicinal concentration to 
determine what dose of medicinal marijuana will be incorporated into the final edible product. 
Once prepared, the final product is also evaluated to determine that it contains the expected dose 
represented by the concentration of the components used in its production (CannLabs; Halent 
Laboratories; CW Analytical). The final edible products, or the oils, butters, and extracts may be 
sold on site or to dispensaries within the same state that do not produce their own medical 
marijuana products, for use or resale, similar to traditional bakeries (Bob).   
Some of the recipes used and developed for medical marijuana edibles, as well as the 
additional ingredients incorporated into the products, have roots from ancient cannabis 
preparations. One ancient confection from Morocco still being made and eaten is known as 
“Majoun,” which translates from Arabic to ‘love potion.’ It requires a very simple preparation, 
using both a hot and cold infusion method, which allows the cannabis to become fully infused 
throughout the mixture. The final product is mixed with dried fruits, nuts, and spices to make this 
Moroccan candy (Appendix D; Wolfert 501). Depending on the product and its use, chefs have 
different points of view regarding flavor. Some chefs prefer to disguise the earthy taste of 
cannabis, enveloping it within the flavors of the products they are producing. Other chefs prefer 
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the flavor to come through, to be used in combination with other foods, creating complimentary 
flavor profiles for their products.  
Dispensaries and Product Developers 
 
 
Chefs and product developers from representative dispensaries in the four states 
investigated have worked to create their own niche in the medical marijuana edible frontier.  Of 
the four states investigated regarding the development of the marijuana edible market, California, 
Colorado, New Mexico, and Rhode Island, three have seen significant growth in their market 
share. Due to regulatory conflicts within the state, Rhode Island’s dispensary production and as a 
result, at this point in time, its medical marijuana edible market is on hold. Therefore, selected 
dispensaries in California, Colorado and New Mexico will be discussed. Each of them, their 
backgrounds, their product development, expertise in the developing market, the challenges the 
market creates and their unique market share will be presented.  
California 
 
California has an estimated 500 to 1,000 medical marijuana dispensaries and collectives 
(Warner). Exact numbers are not available because mandatory registration is not required within 
the state. Two of these, Bhang Chocolates and Kiva Confections in Oakland, California, have 
opened not simply as dispensaries but as bona fide medical marijuana edible businesses.   
Bhang Chocolates, founded in 2010 by Certified Master Chocolatier and Chef de Cuisine 
Scott Van Rixel, sells high quality chocolate products (Cote). Scott Van Rixel studied at Johnson 
& Wales University and subsequently trained in Europe to perfect his skills in chocolate. 
Initially, he owned his own non-medical marijuana chocolate business in New Mexico, known as 
Chocolate Cartel. He relocated to California and became interested in the medical marijuana 
Wolkowicz                       
 
                         46
market as a business decision when California passed its new legislation, Proposition 215. His 
brother, also a Chocolatier, is located in New Mexico producing and distributing the Bhang 
brand there. Since inception, his business has grown significantly.  
To create his signature chocolates, Van Rixel starts with premium “El Rey” chocolate 
made from Venezuelan criollo cacao and cocoa butter. The Venezuelan criollo cacao bean has a 
dark cherry roasted flavor and is found in less than ten percent of cacao beans around the world 
(Vinson). He grows his own cannabis source organically indoors in Oakland, California. 
Van Rixel also chooses to use different strains of cannabis in his chocolates, recognizing 
that different strains provide different medicinal benefits for his patient base. The plants’ 
flowers are ground and then submerged in the hot cocoa butter. The butter is strained and used as 
desired. Van Rixel uses “El Rey” chocolate specifically for the high quality and because it is 
produced organically as well as follows the practice of fair-trade (Cote). From his perspective, 
the flavor of the cannabis plant should not be tasted. Great attention is paid to straining out any 
plant residue to prevent any plant flavor from permeating the final product. Therefore, Van Rixel 
has a blank palate to work with in developing his unique flavor line. In addition, this process 
maintains the smooth consistency and texture desired for the chocolate. Van Rixel and his team 
produce chocolate following the standard procedures employed to create the highest quality 
chocolate, including tempering and molding. All products are tested through CW Analytical to 
guarantee standard doses for patients. It is very important to the Bhang Chocolate company that 
all the concentrations of cannabis are the same, guaranteeing patients a safe, consistent product. 
Their products are made specifically for medicinal benefit, to alleviate pain or address the 
complications of illness (Cote; Vinson).  
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Bhang Chocolates have a loyal client base, ranging from six-year olds with brain tumors 
to grandmothers with cancer, and are a favorite among patients because the quality of the product 
is reliable, effective and delicious. Additionally, patients are drawn to the variety of flavors and 
strengths Bhang Chocolates produce. Since specific cannabis strains used in medical edible 
products are effective for different medical conditions, Van Rixel produces chocolates for his 
patient base marketed to those conditions, which has also resulted in increased growth for Bhang 
Chocolates. Their chocolates are also popular due to the variety of products made available to the 
patient base (Appendix B). Due to their unique product, competition does not affect market share 
and does not pose a challenge at this time.  
Since local regulations in Alameda County do not permit patients to ingest their medical 
marijuana products on site at the dispensaries, Bhang Chocolates is established as a cash and 
carry enterprise. Their hours of operation, as for all California dispensaries, are established by 
state law, which allows sales to be conducted everyday of the week from 8am to 10pm. If their 
business is located 1,000 feet from a school, it must close for one and one-half hours 
immediately following the end of classes (California). One of the methods Bhang uses to brand 
its product is through packaging. The packaging of Bhang Chocolate products is simple and 
clean: the chocolate is placed in an air-tight pouch and then in a black cardboard box, labeled 
with “Bhang” and a notation stating the box contains “Medical Cannabis.” The box is also 
labeled with the flavor of the chocolate, the cocoa content, and, by California law, the dose in 
milligrams of THC.  
As an extension of this market, in the future, Scott Van Rixel is hoping to elevate his 
products from a “black-label” to a “white-label,” using the same Bhang Chocolate but 
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incorporating a non-medical form of cannabis extracted from hemp seeds. Van Rixel is hoping to 
sell this new product line to Neiman Marcus and Whole Foods Market (Vinson).  
Kiva Confections, founded by Kristi Knoblich in 2010, is also located in Oakland, CA. 
Knoblich became involved in the edibles business after being a cultivator for four years. 
Learning that cannabinoids are soluble in fat, and that due to its high fat content, chocolate 
would be an excellent product choice, Knoblich decided to develop a strictly chocolate based 
medical edible business. Her products were developed through trial and error. Now, after two 
years, Kiva Confections has seen significant growth in their market.  
They produce their chocolates on site using a cold-water extract. A cold water extraction 
is done by combining dry leaf material, ice, and water into a basin. The basin is shaken causing 
the trichomes, which contain the highest concentration of THC found in the plant, to sink to the 
bottom. The remaining solution is strained. This is the most effective way to separate the crystals 
from the leaf. The extract is tested for potency prior to being incorporated into the edible 
product. This extract is then added into the chocolate so that the amount of THC remains 
consistent in each bar (Knoblich).  The cannabis that Kiva Confections uses is grown outdoors 
organically and pesticide-free. Unlike Bhang Chocolates, Kiva Confections does not use 
different strains of cannabis in their product. They do not believe that providing products created 
with different strains of cannabis will significantly improve product value to their patient base or 
their market share at this time. Acknowledging that the final edible product should be perceived 
as a medicine, Knoblich believes the flavor of the plant should be tasted in the final edible 
product.  
The chocolate flavors are designed to combine with the medicinal product to elicit 
desirable flavor profiles. For example, Mint Irish Cream or Tangerine Dark Chocolate are flavors 
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used to enhance the taste of medical marijuana (Appendix B). Kiva designs their chocolate bars 
to be divided into four equal parts, suggesting it may be easier for patients to determine dosing, 
allowing them to double or halve their medication if necessary. All flavored chocolate bars 
contain 180mg of THC, whereas the plain bars contain 60mg of THC (Appendix B). All 
products are tested by CW Analytical in Oakland, California to insure consistency and 
reproducibility within the product line. From their point of view, this decision has placed Kiva 
Confections on the cutting edge of their market and ahead in the industry. They have noticed that 
although product testing is not required in California, due to increased awareness amongst the 
patient population, patients are beginning to demand laboratory testing among edible products 
(Knoblich).  
Kiva Confections has a large diverse patient base, although the population is 
mainly comprised of men from twenty to thirty years of age. Product line favorites, such 
as Mint Irish Cream, Tangerine Dark Chocolate, Blackberry Dark Chocolate and Vanilla 
Chai Milk Chocolate continue to draw an increasing patient population. Due to state 
regulations, Kiva Confections, like Bhang Chocolates, is a cash and carry enterprise. 
Their product is also branded by packaging. The chocolate bars sold are packaged in a simple 
and stylish natural cardboard box. The name of the company is printed in black on the top of the 
box, as are the flavor, net weight, child warnings, and, per California law, the concentration of 
THC in milligrams. Ingredients, the mission statement and a UPC code are found on the back. 
Inside the box, an informative insert is enclosed with the product. Since San Francisco has the 
only packaging guidelines for medical edible products, Knoblich decided to design her 
packaging to comply with those guidelines for market access (Knoblich). These guidelines limit 
packaging design so it cannot be attractive to children or present the contents like candy (United 
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States of America, Department of Public Health). Despite the restrictions placed on this market, 
Kiva Confections has only experienced growth in their market share. Demand for the medical 
edible product continues to increase.  
All dispensaries within the California marijuana medical edible market, including Bhang 
Chocolates and Kiva Confections, experience economic challenges. Interstate commerce laws 
prevent these industries from selling product across state lines; therefore their market share is 
contained within the confines of their state borders. Acquiring a medical marijuana business 
license costs $9,000 while, in comparison, a liquor license only costs $250 (Bob). Visa and 
Mastercard do not allow medical marijuana transactions on their credit cards, which limits 
patient flexibility for product purchases. This makes it harder for each dispensary to facilitate 
monetary transactions, and also increases their potential to be a target for crime. Banks are 
reluctant to open or carry accounts for the proceeds of medical marijuana dispensaries due to 
laws regulating money-laundering and drug-trafficking. For the same reasons, investors are also 
hard to find. Although, now medical marijuana edible businesses can establish a Medical 
Marijuana Merchant Account through the Best Point of Banking Bank, a bank that has dealt with 
high risk banking needs since 1993.  Contrary to the tax benefit other business enjoy, these 
businesses are unable to write off their business expenses (Best Point of Banking). 
Challenges also arise in California with respect to dispensary regulations and licensing. 
As noted earlier, each locality has adopted different guidelines for the dispensaries within their 
jurisdiction. Although local regulations regarding both Bhang Chocolates and Kiva Confections 
prevent them from serving edibles for consumption on site, their products can be sold to 
dispensaries in Berkeley and San Francisco, which do allow consumption on site (Knoblich). 
Since there are no mandatory regulations requiring patients to be registered within the state, 
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anyone with a medical recommendation for medical marijuana can cultivate their own plants and 
anyone with a medical recommendation can submit a request for a license to open a dispensary. 
Not all dispensaries are medical edible enterprises, yet new city and county ordinances are being 
put in place to curtail the concentration of dispensaries in specific locations (Warner). Conflicts 
arise regarding the intent of the dispensaries and whether or not they will be defined as illegal 
commercial operations or legally as state recognized medical marijuana providers. The 
California Attorney General has tried to clarify his, as well as the state’s, intent by stating that 
they are not concerned with prosecuting patients or legitimate care-givers operating within the 
law, but are interested in closing down large commercial operations that are making huge 
amounts of money (Onishi).  
Despite these challenges and risks, neither Bhang Chocolates nor Kiva Confections 
believes they outweigh the benefits of operating their medical edible businesses. They believe 
the industry is young and their businesses are experiencing growth and demand. Each of them 
continues to expand their product lines and work on developing new and creative products for 
their patient population. Both enterprises hope and expect to see change in the federal stance 
regarding the regulation of medical marijuana (Cote, Knoblich).  
Colorado  
 
Colorado has a well-established, well regulated medical marijuana market and Denver’s 
market is thriving. Since 2009, the number of registered authorized card-carrying patients has 
grown from approximately 14,000 to over 104,000 in 2012 (Colorado). For perspective, there are 
322 Starbucks stores in Colorado and over 700 medical marijuana dispensaries. Almost 1,100 
cultivars or grow facilities within the state, one-third of which are located in Denver, provide 
plant product for these dispensaries (Warner). Two years ago, the Colorado legislature allowed 
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individual counties and towns more flexibility in interpreting state law, providing for the 
development of a for-profit market. To date, over 100 medical marijuana businesses have entered 
the for-profit market (Colorado Medical Marijuana Code). Three businesses that have entered the 
marijuana medical edible market in Denver are Canna Elixirs, LLC , Dixie Elixirs & Edibles, 
and Julie & Kate Baked Goods, LLC.  
Founded in 2011, Canna Elixirs, LLC developed out of a market steeped in competition. 
The founding professional chef, Eric Underwood, also founded Dixie Elixirs & Edibles. He 
entered the marijuana medical market in 2008 as a patient growing his own plants organically, 
pesticide free, with only $300 to his name. Not formally trained by a culinary institution, he 
came to the market with a culinary restaurant background. Recognizing the potential for growth 
within this industry, Underwood decided to investigate the idea of producing a unique medical 
edible that would be created in the form of a beverage. Experimenting with sauces and 
carbonation techniques, he was able to develop the first medical marijuana soda and is credited 
within the industry for that accomplishment. This product revolutionized the medical edible 
industry. Initially, his business was known as Dixie Flyer Farms and the new medicinal sodas 
were labeled as “Dixie Elixirs.” These sodas, as well as the chocolate truffles and sublingual 
tinctures Underwood developed were sold through over 100 dispensaries he managed. Being 
naïve to the protection patent rights for his products would have provided, Underwood did not 
take steps to patent his unique formulas for the sodas, truffles, or tinctures he created. In 2010, 
the dispensaries he produced and sold his products through were taken over by a new, rival 
medical edible enterprise. This business absconded the recipes and formulas Underwood 
developed, using them to acquire funding for a new start-up enterprise. The resulting business 
became Dixie Elixirs & Edibles and patented the formulas developed by Underwood, now being 
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sold and distributed as Dixie Elixirs Carbonated Beverages (sodas), Dixie Medicated Chocolate 
Truffles, and sublingual tinctures known as Dixie Elixirs Dew Drops (Underwood; Lunsford).  
Despite this market challenge, Eric Underwood developed a new proprietary medical 
edible business known as Canna Elixirs, LLC. Now, through Canna Elixirs, LLC, Underwood 
has his own production facilities which create hand-crafted medical edible products, such as 
caramels known as Canna Chews, Canna Drop Cookies, and sodas distributed as Canna Elixirs. 
Based on scientific medical research, Underwood uses Sativa and Indica strains in his products 
to provide his patient base with edibles that are effective for different medical conditions. His 
facilities grow their own cannabis organically and pesticide free. All products are laboratory 
tested (Underwood).  
Canna Elixirs, LLC continues to grow and its patient population continues to expand. 
Currently Canna Chews are its most popular medical edible. In addition to this unique product 
offering, Underwood also uses packaging to brand  his medical edible line, labeling each item 
with the word ‘canna’ in an easily recognizable font. All Elixirs are packaged in clear, twelve 
ounce glass bottles labeled to indicate the flavor and that the contents are infused with 100mg of 
medicinal marijuana. Canna Chews caramels are produced in 50mg, 100mg and 200mg doses 
using Sativa, Indica or a Hybrid in each, which is also indicated on the label. Canna Elixirs, LLC 
continues to expand its product line working on the development of new edibles, such as Hemp 
milk ice cream (Underwood).  
Originally founded in 2009 by Eric Underwood, Dixie Elixirs & Edibles has grown into 
what is now a brand product line of Red Dice Holdings, which is a portfolio company of Medical 
Marijuana, Inc. (OTC Stock Review). It produces product lines that are sold to over 500 legal 
medical marijuana dispensaries throughout Colorado.  Currently, the medical marijuana edibles, 
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which include a wide range of beverages and ice creams, are produced within a 27,000 square 
foot manufacturing facility. On October 21, 2012, Dixie Elixirs & Edibles was featured on a 60 
minute segment called Rocky Mountain High. During this segment, the growth of the medical 
edibles market was discussed and it was noted that this industry had created thousands of jobs, as 
well as millions of dollars in tax revenues for medically legalized states (CBS News).  
Since 2009, Dixie Elixirs & Edibles has experienced unprecedented growth. Christie 
Lunsford, Director of Marketing and Sales at Dixie, joined the company through a merger of her 
own previous business, Cannabis Magic, to form a subsidiary known as Dixie Botanicals. Dixie 
Botanicals serves as a non-edible medical off-shoot of Dixie Elixirs & Edibles, producing topical 
medical marijuana products.  Lunsford has been in the medical marijuana market for five years. 
She has a background in caregiving and wanted to help when she saw that people’s suffering 
could be eased through medical cannabis. Lunsford believes that cannabis can help “soften” the 
pain and anxiety felt by patients, allowing them to live an easier, more comfortable life. As a 
member of the Dixie Elixirs & Edibles team, she lauds their products, explaining the company 
produces their own products in a state of the art medical marijuana facility (Lunsford).  
The cannabis used in their products is grown organically in well-flushed soil to keep the 
pH of the soil balanced and to remove any wastes excreted by the plant. Infusion techniques, 
which vary based on the products being produced, are used to incorporate the cannabis into the 
products used to produce edibles. Dixie believes it is important to allow the plant flavor to come 
through into the edible. From their perspective, they are producing medicinal products and the 
taste of those products should reflect the flavor of the therapeutic botanicals used to develop 
them. The concentrations of cannabinoids in each product are very accurate due to laboratory 
testing, and are noted on the packages in milligrams of THC according to state law (Lunsford).  
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Dixie Elixirs & Edibles sells a host of edibles, tinctures, tonics, and beverages. All of 
their products are tested through CannLabs and are of the highest quality. Their beverages are 
produced in a variety of flavors and contain a low dose infusion of 40mg THC. Their chocolate 
truffles, produced with concentrations between 50mg to 300mg of THC, are the most popular of 
the vast array of medical marijuana edibles they produce, which includes items such as pastries, 
candies and ice creams (Appendix B). All products are sold in well-labeled, childproof 
packaging. For convenience, patients may order their medical edible products online in 
Colorado. The patient population they serve is diverse and extends throughout the state 
(Lunsford)  
In 2010, redeveloped their marketing strategy. Due to a rapidly growing field of 
competitors, they changed their product label to brand their name. As a result, they now have an 
extremely unique label, which is used on all of their product lines (Lunsford). According to 
Tripp Keber, president of Red Dice Holdings and managing director of Dixie Elixirs & Edibles, 
the medical marijuana industry will be a $9 billion per year business nationwide by 2016. He is 
planning to expand market share and open franchises  in four states under the Dixie X brand, 
which will produce medical marijuana products without euphoric effects (CBS News). 
 Julie & Kate Baked Goods developed and entered the market as a wholesale 
manufacturer of medical edible products from its inception in 2010. Each of its founding 
members brings different, individual skills and professional expertise to the business.  Kate 
brings with her graphic design experience, which helps with product label design and marketing. 
Although lacking formal culinary training, she loves to bake and is passionate about the 
medicinal benefits patients can derive from medical marijuana. Julie Dooley comes to the 
business with previous financial training. She also loves to bake and has a knack for creating 
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delicious, healthy, gluten-free products. Personally, a patient with Celiac disease, Julie is limited 
to consuming products made only from gluten-free ingredients. Experiencing first-hand the 
limited number of gluten-free medical edible products available, she determined this was an 
untapped market and she could fill the market need. She and Kate developed a short list of 
healthy products they decided to market throughout the state, creating a niche for themselves. 
Their medical edible products are produced from cannabis plants they cultivate themselves 
indoors, off-site. All plants are grown organically and pesticide free. Kate has developed a 
proprietary, methodical cannabis-infusion process using clarified butter, which she claims helps 
to maintain the creamy taste for their products and a longer shelf-life. Additionally, this process 
helps to avoid impurities and limit the concentration of saturated fats in the product. The flavor 
of the cannabis plant is intended to be experienced in the edible Different cannabis strains are 
incorporated into the products, which also provides different flavor profiles. The flavor is 
intended to reflect the fact that Julie & Kate’s Baked Goods are medical marijuana products and 
is not intended to mimic sweet treats. Their product line is limited to clarified cannabutters, 
infused with different strains of medical marijuana, a roasted seed mix, a granola, and nutty 
bites, the most popular of which is the roasted seed mix because it appeals to a broader customer 
base as well as being more cost-effective than the other products offered (Appendix B). All of 
their products are tested by CannLabs in Denver for product safety and accurate concentrations 
of THC (Dooley).  
Julie & Kate Baked Goods are in competition with at least twenty other wholesale 
medical edible manufacturers. Since they specialize only in gluten-free, healthy medical edible 
products, Julie & Kate Baked Goods do not experience direct competition. They have managed 
to develop an effective niche market for themselves, with an avid customer base, selling to over 
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100 dispensaries. Their product line is also branded by unique labeling and packaging, including 
ingredients as well as the concentration of THC in milligrams (Appendix B). Due to product 
recognition and quality, sales have increased steadily each month by 25% to 45%, and a 50% 
increase in total sales has been experienced since 2011 (Dooley).  
All medical marijuana dispensaries in Colorado are visibly distinguishable by the 
presence of a green cross displayed outside of each establishment. Well-defined state regulations 
regarding the sale and distribution of medical marijuana products have actually enhanced the 
development of this market rather than hinder it. These regulations help direct individuals 
involved with the industry as patients, care givers, and medical edible product developers, 
providing them with the necessary guidelines to effectively function within the medical 
marijuana market. Compassionate and supportive legislators have helped to create a foundation 
for more effective business practices, as well as more effective medical marijuana access for the 
patient base. As a result, this industry has provided more jobs and a more revenue through taxes 
for the state. A variety of medical edible business models are allowed to exist within the 
parameters the law, such as small, individually owned dispensaries, larger wholesale product 
manufacturers, such as Dixie Elixirs & Edibles, or mid-size wholesale producers. Despite 
competition within the market, new dispensaries are still able to enter the market, such as Canna 
Elixirs, LLC. Banking restraints within Colorado still pose financial challenges to medical 
marijuana business owners, whose accounts are often prevented from access to credit cards and 
are limited to only cash or check transactions, which puts them at risk for theft. Although, the 
recent regulations regarding agent-monitored video feed in all shops does help to limit their 
potential risk for crime. Despite these challenges and risks, the individuals pursuing the medical 
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marijuana market in Colorado perceive this to be a developing and growing market with great 
potential for the future.  
New Mexico  
 
New Mexico’s medical marijuana market is also growing. Its strict cultivation laws limit 
the developing medical edible business to arise only from state licensed dispensaries (N.M. Stat. 
Ann. §26-2B-1). Since individual patients are not allowed to grow their own medical marijuana, 
no patient can legally develop their own “mom and pop” dispensary.  Nevertheless, the medical 
edible market is growing through the currently licensed dispensaries due to high patient demand.  
Of these dispensaries, two in Albuquerque, New Mexico, Minerva Canna Group and The Verdes 
Foundation have seen great potential in their state for this new edible frontier.  
The Minerva Canna Group was founded by Erik M. Briones in 2010. A degreed 
horticulturalist and owner of Purple Sage Garden Center, who closed his business and retired 
after the economic crisis in 2008, Briones decided he was perfectly situated to enter the medical 
marijuana business after New Mexico began their medical marijuana program. As an authorized 
patient, his education and expertise with botanicals coupled with his business savvy, gave him 
unique credentials for entering this industry. He is the only producer of medical marijuana in 
New Mexico with a degree in horticulture.  
Meeting patients who preferred, or could not smoke marijuana, Briones recognized the 
need to create edible products. His dispensary grows marijuana for medical purposes indoors, 
organically, in soil as opposed to hydroponically. He grows plants of various strains to 
incorporate into his edible products so patients can experience the medical benefits provided by 
each strain. The cannabinoids are extracted through infusion processes into butters, oils, 
tinctures, and vegetable glycerines. These compounds are used to produce a wide range of 
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medical edible products (Appendix B) . Briones prefers to mask the flavor of the cannabis plant 
in the development of his edible products. Although laboratory testing is not yet required by the 
state, all of Minerva Canna Group’s products are tested by Page Analytics in Albuquerque for 
concentrations of THC. Doses are determined based on the Donald Abrams standards (Appendix 
C; Briones).  
In New Mexico, patients are required to obtain their medical edible products from 
licensed dispensaries. Due to this requirement, and other enforced New Mexico medical 
marijuana laws, there is little to no competition in the medical edible market, contrary to the 
experience in Colorado and California. Since opening its doors two years ago, Minerva Canna 
Group has seen exponential growth. They started their business with no patients and now serve a 
patient population of 1,600. In one year alone, Minerva has experienced over 200% growth. The 
highly regulated market draws patients who have been diagnosed with one of the fifteen state-
approved uses for medical marijuana. The patient base tends to be well-educated, spanning 
across socio-economic boundaries, and an average age of 55. For brand recognition, they have 
developed their own logo which is incorporated into all of their product packaging, including the 
ingredients used and the dose of THC in milligrams for each product. No specific packaging or 
labeling guidelines have been established for New Mexico dispensaries so Minerva uses a 
variety of see-through plastic or foil-sealed bags, and bottles for their products.  Over the past 
two years, their signature edible products have become popular amongst their patient population. 
Canna Colas, Lemon Bars, Cappuccino Crisps and gummy candies are patient favorites. For 
patient convenience, orders may be called in or ordered on line and a convenient pick-up location 
has been established in a more central location in Albuquerque.  Patients cannot consume any 
product on-site (Briones). 
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Minerva Canna finds it is hard to keep up with patient demand due to the limitations the 
state has put on the medical marijuana producers, which only allow for up to 150 plants per 
dispensary regardless of the number of patients each dispensary serves. It is difficult to establish 
a bank account due to the current federal restrictions on the sale of medical marijuana. Despite 
these challenges and risks, Erik Briones is committed to this venture. He sees a real need and a 
real benefit for the medical edible marijuana business in New Mexico, and by extension, in the 
United States.  His intent is to work within the guidelines established by his state to continue 
to  meet the needs of this new and growing market.  
 The Verdes Foundation was established in 2011 by a group of five individuals, three of 
whom are “qualified medical cannabis patients.”  The founder and Chairman of the business is 
also a registered medical cannabis patient producer.  Each of these members offers specific skills 
to the business. The founder has over thirty years of financial and business experience. He served 
as president and a board member of the New Mexico Bankers Association.  An optometrist, IT 
developer, computer network engineer, and a landscape designer/horticultural expert with thirty-
five years experience complete the business team. Their medical edibles market grew out of their 
interest in providing patients with a longer, lasting, medically effective product that did not 
require smoking (The Verdes Foundation). 
They grow the medical cannabis used in their products outdoors,  at a high tech facility 
under experienced horticultural direction.  Strict guidelines are employed to produce a clean, safe 
product without pesticides or plant hormones. Different strains are used in the production of 
edible products to provide patients with the varied medicinal benefits. Infusion techniques are 
employed to extract the cannabinoids from the plant material using butter. Since laboratory 
testing is not required by the state, The Verdes Foundation do not have their products tested. 
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Also, as a result of no state requirement, the dosing of their products is determined by calculation 
by weight.  Each individual edible product is prepared to contain approximately ¼ gram of 
medical cannabis. This information is included on the product labels along with the other 
ingredients used in each edible (The Verdes Foundation). 
Their product line which is composed of brownies, lemon bars, oatmeal cookies and an 
Indica Chocolate “Sleep Cookie” is well received by the patient population.  The Verdes 
Foundation only sells products they produce in their dispensary and do not carry other product 
lines to sell to their patients.  They have developed their own label and use opaque packaging for 
all their products.  Patients must place their orders in advance, either by phone or online.  Pick up 
is on site or, for patient convenience, delivery is available for a flat fee. Patients are able to pay 
for their medical edible products using a credit card (The Verdes Foundation). 
The Verdes Foundation has experienced growth and satisfaction in knowing they are 
providing a much needed medical benefit to their community.  They also choose to remain 
committed to this market frontier and see greater potential for its growth as federal regulations 
catch up with the states that have already recognized the need to legalize cannabis for medical 
use (The Verdes Foundation). 
Currently there are fourteen licensed medical cannabis producers in New Mexico. The 
criteria set by the state regarding the licensure of producers or dispensaries has limited the 
number of  licensed dispensaries available for patient access. Each licensed dispensary is limited 
to a maximum number of plants, despite the population of patients they serve, which results in an 
inability to have enough product to meet  patients’ needs, creating a back-log for patients. This is 
a serious  and frustrating challenge for the dispensaries, which they hope will be addressed soon 
by the legislature (Briones). It is also difficult for producers to handle the financial requirements 
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of their business. Banking institutions are reluctant or refuse to open accounts designated for 
medical cannabis producers. Managing proceeds and acquiring products for the development of 
inventory becomes a complicated process. Despite these challenges and the risks associated with 
them, both of these medical edible producers see a future for this market and plan to remain 
committed to its progress (Briones; The Verdes Foundation). 
 
Rhode Island  
 
According to the Rhode Island state Health Department in October 2012, it is in the final 
stages of completing its revised regulations regarding compassion care centers. Subsequently, 
representatives from the three certified compassion centers or medical marijuana dispensaries, 
Thomas C. Slater Compassion Center in Providence; Summit Medical Compassion Center in 
Warwick and Greenleaf Compassionate Care in Portsmouth, will submit ‘registration to operate’ 
applications for licensure. Principals and spokesmen for Slater and Greenleaf anticipate that they 
will begin selling medical marijuana to nearly 5,000 patients shortly after January 1, 2013 
(Malinowski ;Rhode Island Department of Health).  
Although marijuana has been approved for medical use in Rhode Island since 2006, and 
patients have had access to the plant for individual use, no medical marijuana products have been 
available for distribution for the authorized patient market due to complications surrounding the 
licensing of compassion centers. This market will be facing its debut as of the onset of 2013, 
creating a unique opportunity for culinary entrepreneurs within this market and a frontier for 
medical edible products in Rhode Island (Rhode Island Department of Health). 
The medical edible marijuana market has developed in every state that has legalized 
marijuana for medical use.  Although business models vary from state to state, of those states 
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investigated, each has a thriving medical edibles industry that operates within the confines of its 
individual state regulations and federal restrictions. The process of thoughtful implementation of 
these regulations improved the quality of this market from state to state, improving oversight in 
the industry, the quality of the product, product development, access to the market and 
availability to the patient base. Yet, in each state, much remains to be done to assist with the 
challenges and risks producers face economically.  
The most sophisticated market is found in Colorado. Although it legalized marijuana for 
medical use much later than California, its well-defined regulations enabled its medical edibles 
market to develop more effectively. Uniform state wide laws applied in both Colorado and New 
Mexico prevent discrepancies from developing between counties or cities with respect to 
cultivation and distribution in contrast to the Californian model, which varies from county to 
county. The creation of an authorized patient database has served both the Colorado and New 
Mexico medical edible market. By overseeing the growing patient base, as well as the location 
and number of dispensaries, these states are able to confirm the industry within their borders is 
operating in compliance with regulations (Colorado). In contrast, by not mandating a patient 
registry, California is unable to follow the growth of the patient population or the location and 
density of its licensed dispensaries, which has now caused controversy within specific counties.  
Colorado requires their producers to indicate the concentration or dose of THC in each 
product, although at this time dose is not required to be determined by laboratory assessment 
(Lunsford). Due to competition, most leading dispensaries in the market test their products, not 
only for dose assessment, but also to prove product consistency and safety (Knoblich). 
Colorado’s dose labeling has moved the industry in the state forward toward uniform, scientific 
methods of testing to ensure reliable accuracy and safety in medical edible products (CannLabs). 
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By contrast, both California and New Mexico do not require producers to label the concentration 
of THC in each product (Cote; Briones). Although, in California, high end producers all choose 
to use laboratory testing and label their products’ doses in concentration of THC in milligrams 
(Knoblich; Cote). In New Mexico, each of the dispensaries described label their products, but not 
uniformly. One dispensary chose to test their products scientifically, while the other chose to rely 
on in-house methods to determine accuracy by weight, which creates inconsistency within the 
market and for the patient population (Briones; The Verdes Foundation). Patients benefit from 
and, increasingly informed patients expect to know, what dose of medicinal component, the 
effectiveness of that dose, and the duration of the effect to expect from each edible product.  
All product developers entered the medical edible market as patients from varying 
culinary backgrounds or experience. Their growth as entrepreneurs in the market varies with 
respect to their personal understanding and ability to create unique, flavorful, effective edible 
products as well as their own, or access to those with, business experience. Chefs with 
professional training and culinary skills, such as Scott Van Rixel from Bhang, and Erik 
Underwood from Canna Elixirs, LLC., via Dixie Elixirs & Edibles play an important role in this 
industry. They usually are the leaders in product development, using their culinary skills to 
formulate distinctly new edibles and flavors that either incorporate or enhance the flavor of the 
cannabis plant into the product, or eliminate it altogether. Knowing how to artistically brand and 
market their product is also a key to their success. Product developers coming into the market 
with previous horticultural or cultivation experience can drive the process of developing more 
effective medical marijuana strains to incorporate into the edible product for the benefit of their 
patient base. These are individuals from dispensaries such as The Verdes Foundation; Eric 
Briones from Minerva Canna, Inc.,; and Kristi Knoblich from Kiva Confections. Being patients 
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themselves, many individuals enter the edible market through personal needs and experience or 
from relationships as caregivers such as Christie Lunsford from Dixie Elixirs & Edibles or Julie 
Dooley from Julie & Kate Baked Goods, LLC. Their individual needs or experiences drew them 
away from the traditional, inhalation methods of receiving the benefits of medical marijuana to 
experimentation with the medicinal potential of edible products. All producers concede that the 
medicinal effect from edible products is longer lasting and more beneficial than inhalation.  
The growth of this industry remains hampered by federal regulations. Due to interstate 
commerce laws, concerns about money laundering and drug trafficking, many banks are 
unwilling to open accounts for medical edible businesses. Credit cards are unwilling to process 
financial transactions originating at dispensaries. In states where twenty-four hour agent 
monitored video surveillance is mandated, there is less risk of crime for these businesses, but for 
those entities with little to no surveillance, the cash and carry model is challenging. In Colorado, 
the Maverick bankcard has become available through dispensary owners and operators. In 
California, the Best Point of Banking bank is now opening accounts for dispensaries, it is also 
available to dispensaries in New Mexico (The Best Point of Banking Bank). Establishing a 
dispensary requires a far more expensive business license than standard businesses and the 
standard business tax deductions are not available. Yet, despite all of the regulatory and financial 
complications, not one medical edible producer believes the risks outweigh the benefits of their 
ventures. Every one of them has experienced substantial growth, gaining market share and an 
increasing patient population. Some, like Dixie Elixirs & Edibles, have seen exponential growth 
and are venturing into other markets with non-euphoric products. Eric Underwood, with Canna 
Elixirs, LLC., has reinvented his brand and experienced success since the devastating set-back 
experienced in losing the Dixie line. Bhang Chocolates of California has expanded its market 
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through Scoot Van Rixel’s brother, who remains in New Mexico and has developed the Bhang 
brand in that market. These are the pioneers in a frontier market who understand the challenges 
they face and see the rewards their commitment to this market has brought in benefits to their 
patients, their craft and the products they continue to produce.  
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Chapter Four 
Data Acquisition: The Edible Market 
Methodology 
 
Two surveys were designed to acquire data pertaining to the development and growth of the 
marijuana medical edible market, each individually directed to a different cohort: one designed 
for product developers, the other designed to preserve anonymity for the patient population. The 
survey designed for the dispensaries and product developers contains twenty-four open-ended 
questions (Appendix A). The survey designed for the patient population contains a combination 
of  seventeen multiple-choice and close-ended questions, accessible through the fluid surveys 
website (Appendix A). The purpose of these surveys was to find out personal viewpoints from 
clients of dispensaries and their opinion of edible marijuana, as well as to obtain as much 
information as possible about this new market frontier from the entrepreneur producers of edible 
marijuana products.   
The dispensary and product developer survey used open-ended questions for the purpose of 
acquiring as much information as possible about how they became involved in the marijuana 
medical edibles market, their experience and place in the industry, limitations, and how 
regulations affect market development. Further questions explored product development, 
packaging, and market response. The anonymous patient survey contained questions developed 
to discover their demographic profile and medical need for the consumption of medical 
marijuana.   In addition, questions were used to evaluate product choice based on: medicinal 
effectiveness; safety and quality; flavor preferences; and product type.  Information was 
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requested to determine producer or dispensary loyalty, if a restaurant model would be embraced, 
and the preferred ambience of a dispensary.  
Thirty dispensaries located in California, Colorado and New Mexico, were contacted via 
email and phone to conduct and complete the product developer survey. These thirty retailers 
were also asked to direct their patients to the survey site at fluid surveys. Additionally, links were 
provided through the dispensaries’ Facebook sites to connect visiting patients to the survey. The 
entire survey sample is intentionally selective, based on the legal constraints enacted to limit the 
use of medical marijuana only to medically authorized individuals. Additionally, that population 
was further narrowed to the individuals who responded to the dispensary product developer 
survey and their patient population. Of the thirty dispensaries contacted, nine replied, it is from 
these dispensaries that the product developer data is obtained (Appendix B). Seventy-one 
patients provided responses for the patient survey.  
Both surveys had several limitations. A substantial limitation was the geographical location 
of the participants, which prevented personal access for follow-up or data acquisition, and may 
have limited the responses obtained. Despite allowances for adequate response time, the results 
were limited to and dependent upon the turn-around time chosen by the respondents for both 
surveys. The validity of the data is limited to the honesty of each responder. Multiple-choice 
questions limit, although efficient in acquiring data from both an interviewer’s and responder’s 
perspective, do limit the response to only the choices made available.  
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Results  
 
The following sections will include graphs that reflect data obtained from the two surveys 
conducted (Appendix A). The first set of graphs, labeled RD 1 to RMC 3, reflect data obtained 
from the product developers, dispensaries or vendors. The next set of graphs, labeled PD 1 to P 
11 reflects the data obtained from the patient population. The graphs are not presented in the 
numeric order of each surveys’ questions. They are grouped based on topic. The number of each 
corresponding question per survey type is located in the upper left hand corner of each graph. 
The product developer’s survey data is grouped into six sections: demographics, cultivation, 
product testing, edible development, marketing and market challenges. The patient population 
survey data is grouped into seven sections: demographics, medical reasons for medical marijuana 
use, cultivation, quality and dosage, medication preference, edible preference, taste/flavor of 
products, and dispensary loyalty and presentation.  
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Product Developer/Dispensary Results 
 
Retail Demographics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   Fig. RD 1. 
Fig. RD 1. 
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     Fig. RD 2.            Fig. RD 3. 
 
 
Fig. RD 4. 
The figures RD 1 through RD 3 reflect the demographic responses of the nine medical 
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Mexico, including their paths of entry into the market. Figure RD 4 reflects their perspectives 
regarding the risks associated with using the use medical marijuana as an alternative to 
traditional medication.  
The data reveals that, of those developers interviewed, most have four or fewer years in 
the medical edible industry. Although Scott Van Rixel only developed and débuted his Bhang 
product line in 2010, he has been creating medical edible products for sixteen years. Each of the 
product developers has spent at least equal time in the edible industry, prior to establishing their 
own business. Most developers have spent more time in the industry developing their products 
before branding their business model.  
Recognizing each developer could only enter the medical edible market as a patient first, 
figure RD 2 reflects a variety of paths into the market. Over forty percent of the product 
developers entered the market as chefs, followed by cultivation. Some individuals were drawn 
into the market through care giving and medical concerns. The majority of medical edible 
product developers had either a strong or professional understanding of culinary techniques or 
they had strong horticultural skills (Fig. RD 2). Implying, these skill sets provided a natural 
transition into the medical edible industry.  
Figure RD 3 reflects the medical benefits each product developer strives to provide 
through their edible products. Although there is a fair balance of medical benefit demonstrated, 
pain relief is regarded as most beneficial. Without hesitation, all product developers agree 
unanimously that the benefits of medical marijuana outweigh the risks, providing little chance 
for fatal overdose or any of the complicated side effects associated with traditional medications 
prescribed for the same purposes (Fig. RD 4).  
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Cultivation 
 
Fig. RC 1.  
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Fig. RC 3. 
Fig. RC 4. 
Figures RC 1 and RC 3 reflect information provided by the dispensaries and product 
developers regarding cannabis cultivation. This data correlates with state laws governing where 
and who can cultivate cannabis for medical purposes. How the plants are cultivated for medical 
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purposes, indoors or outdoors, is also defined by state laws. Figure RC 1 reflects a nearly equal 
distribution of plant growth locations by the dispensaries that grow their own cannabis. Only 
California dispensaries are required to cultivate plants indoors, depending on county regulations, 
while growers in both New Mexico and Colorado also choose to grow their cannabis indoors. 
Therefore, the data in figure RC 1 reflects an equal distribution of growth location choice.  
Figure RC 2 reflects the stringent cultivation regulations enacted by New Mexico state 
law, showing New Mexico to be the only state that requires cannabis to be only grown at 
licensed dispensaries. This is also reflected on figure RC 3 which shows that patients are not 
allowed to grow their own cannabis in New Mexico, while in both Colorado and California, 
patients are not prevented from growing their own, nor is cannabis required to be grown 
exclusively at the dispensaries. A business must be a licensed dispensary to sell or distribute 
medical edibles. Figure RC 4 shows most dispensaries produce edible products for sale, but not 
necessarily retail.  Some dispensaries in Colorado, like Preferred Organic Therapy, do not 
produce their own product but choose to sell retail.  
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Product Testing 
 
 
 
Fig. RPT 1.  
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The quality control of products is a process that all product developers take extremely 
seriously. All products contain a specific amount of cannabis,, which is determined through 
testing.. As indicated by PT.1, all the product developers surveyed determine the dosage of their 
products through laboratory testing, except for the Verdes Foundation, which determines the 
dosage by the weight of the cannabis (PT.1). The product developers label their products with 
the amount of THC, with the majority labeling with the dose amount, whereas The Verdes 
Foundation labels only with the weight. This is because they do not test their product through a 
laboratory, so they would not be able to determine an exact dose (PT.2).  Colorado is the only 
state of the three surveyed that requires the products to be labeled with the THC concentration 
(PT.3). There are several laboratories used to test the cannabis products, and in Colorado, all of 
the dispensaries surveyed test through CannLabs. In California, Kiva Confections and Bhang 
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Chocolates both use CW Analytical, while Auntie Dolores uses Halent Laboratories. The 
Minerva Canna Group in New Mexico uses Page Analytics and the Verdes Foundation does not 
use a laboratory, relying on self-regulating procedures instead (PT.4).  
Edible Development 
   Fig. RE 1 
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 Fig. RE 4.  
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Fig. RE 5. 
The primary factor in edible development is the incorporation of cannabis into the edible 
product. Figure RE 1 presents the various ways these developers incorporate cannabis into their 
product.  Most product developers use infusion methods with butters, oils or fats. Canna Elixirs, 
LLC and Minerva Canna Group make products using vegetable glycerin. Kiva Confections 
employs a cold-water extraction process to collect a greater concentration of cannabinoids before 
infusing the product into fats. Products created and sold by Dixie Elixirs & Edibles, Canna 
Elixirs, LLC, Preferred Organic Therapy, Minerva Canna Group are produced using various 
proprietary extraction and infusion techniques, such as carbon dioxide and nitrogen dioxide.  
In the process of developing the edible, most producers have developed and choose to use 
techniques by which the cannabis does not affect the consistency or texture in a final product 
(Fig. RE 2). Additionally, the decision to mask or allow the cannabis flavor to be experienced is 
part of this process. The product developers are almost equally divided in terms of their decision 
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to mask or incorporate the flavor of cannabis in their final product (Fig. RE 3). Many of the 
product developers have discovered specific flavors that enhance medical marijuana products, as 
noted in Figure RE 4, the most popular of these being chocolate. From a medicinal perspective, 
product developers create edibles to provide medical benefits for their patient population. In 
Figure RE 5, each product developer, the strains they use, and the purpose for using those strains 
is presented. Most developers use the different cannabis strains, C. Sativa and C. Indica, to 
provide their patient base with effective targeted medicinal benefits. Although most product 
developers indicated various beneficial medical effects were experienced by their patient base 
using different strains of cannabis,  C. Sativa is generally used for pain relief, while C. Indica is 
generally used to combat insomnia. Scientific medical research is helpful in providing these 
developers with useful information to create edible products geared for patients’ needs.   
 
Marketing 
 
 
81% 
11% 
8% 
Customer Demographics by Age 
Diverse Age/
Gender 
Men 20s-30s 
Avg. 55 
Kiva Confections, CA 
Minerva Canna Group, NM 
*12. 
Wolkowicz                       
 
                         82
Fig. RM 1. 
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Fig. RM 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. RM 6. 
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DO DISPENSARIES HAVE EAT-IN OPTION  
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Recently, marketing has become a significant factor for product developers and their 
dispensaries. The majority of dispensaries (81%) surveyed serve a diverse clientele, 
incorporating all ages and genders, although Kiva Confections serves a patient population that is 
predominately male, between twenty and thirty years of age and Minerva Canna Group serves a 
population that is predominately older than fifty-five (RM.1). Each dispensary markets a product 
that has proven to be most successful for their market share. These products are noted in figure 
RM 2. ranging from Canna Elixir’s Canna Chew Caramels, Bhang Chocolate’s Fire Chocolate 
and The Verdes Foundation’s Indica “Sleep Cookie,” The criteria that have led each product to 
success, in order of significance, include flavor, medicinal benefit, price and size. Flavor is the 
most influential driving force next to medicinal benefit for marketability (Fig. RM 3).  
Only San Francisco and Berkeley, California have packaging restrictions for medical 
edible products (Fig. RM 4). In response to those restrictions, product developers in the 
California market, such as Bhang Chocolates, Auntie Dolores and Kiva Confections, have 
created compliant packaging for market access to those localities. Product developers within 
California and Colorado have embraced product branding, or logo development. In New Mexico, 
where the number of dispensaries and competition is limited, branding has not affected market 
share (Fig. RM 5).  
In Colorado and the Berkeley/San Francisco areas of California, it is legal to eat medical 
edible products within the dispensaries (Fig. RM 6). In all other regions of California and the 
state of New Mexico, medical edibles cannot be consumed inside the dispensaries. Despite this 
legal latitude, only one Colorado dispensary, Preferred Organic Therapy, serves edibles within 
its establishment (Fig. RM 7). The majority of product developers believe that eventually, the 
market would support full edible meals of medical marijuana (Fig RM 8). 
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Figure RM 9 presents the growth of this market in sales experienced by each dispensary. 
All of the product developers have experienced significant growth in sales, while 22% has 
experienced over 50% growth, and the Minerva Canna Group has experienced over 100% in 
growth.  
Challenges in Industry 
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Product developers face several challenges in the industry, most notably, legal 
challenges. The product developers surveyed were split nearly in half when asked if they thought 
legal issues limited the medical edible business from expanding, some saying definitively yes, 
while others agreed that some regulation was necessary (Fig. RMC 1). They agreed 
unanimously, however, that the economic and legal risks of the market did not outweigh the 
benefits (Fig. RMC 2). The major obstacles most product developers (67%) faced was finding a 
bank that would support them and allow them to create accounts for their businesses (Fig. RMC 
3).  
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Patient/Client Results 
Patient Demographics 
Fig. P 1. 
Fig. P 2.  
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There is a relatively even distribution of medical edible patients across age barriers. The 
greatest response came from males between 18 to 35. The female population was evenly 
distributed between ages 26 to 64.(Fig. PD 1). Most of those responding have had college or 
graduate school education (Fig. PD 2).  
Medical Reasons for Medical Marijuana Use 
Fig. P 3. 
  
When asked to explain the purpose for medical marijuana use, of the illnesses noted in 
figure P 3, the majority of patients responded with “other,” which includes seizures, insomnia, 
emphysema, fibromyalgia and migraines. The two other leading reasons for medical marijuana 
use include pain management and anxiety/depression (P 3).   
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Standards in Cultivation, Quality Control and Dosing 
  
Fig. P 4. 
 
The majority of patient responders indicated that cultivation, quality control and dosing 
of the product was important to them. 84% of those interviewed were concerned about having a 
safe product, over 70% were concerned about strict cultivation standards and approximately 62% 
believed scientifically determined dosing of the product was important (P.4). 
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Medication Preference 
 
 Fig. P 5. 
 
 Of those interviewed, patients clearly prefer edible products over smoking in a 2 to 1 
ratio (48:23) and, in an 8 to 1 ratio (63:8), patients preferred having access to medical marijuana 
edibles over standard medication (Fig. P 5).  
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Edible Preference 
 Fig. P 6 
 
In terms of edible preference, the majority of patients responding preferred sweet 
products, chocolates or candies. Approximately 14% of those interviewed had a preference for 
savory products or beverages. “Other” included responses such as healthy/no sugar, more than 
one of the options above and self-made glycerin tinctures (Fig. P 6).  
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Taste/Flavor of Edible 
 Fig P. 7 
 Fig. P 8. 
Almost 60% of the patients surveyed (forty-one out of the seventy-one patients surveyed) 
preferred having the taste of marijuana masked in their edibles (Fig P 7). The flavors most 
patients chose to enhance the medical marijuana product were coffee (23) and chocolate (21) 
(Fig P 8).  
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     Fig. P 9     Fig. P 10 
 
 
Fig. P 11 
 
Figure P 9 addresses dispensary loyalty. The majority of the patients interviewed would 
prefer to use the same dispensary, indicating a degree of patient loyalty. Approximately 70% of 
the patient population believed the presentation of the edible mattered (Fig. P 10), and over 70% 
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of the population interviewed stated they would frequent a medical marijuana café if it were 
available and that the ambience of the establishment would make a difference (Fig. P 11).  
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Chapter Five: Conclusion 
The historical and legal perspective of cannabis, its relationship between food and 
medicine has come full circle. Its benefits as a bona fide medicinal agent continue to be revealed 
through research by scientific and medical communities. Additionally, its ability to be 
transformed into an edible product has provided a unique access for the blend of its nutritional 
and medicinal properties to an increasing patient population. 
With a growing number of states within the United States legalizing the compassionate 
use of cannabis for medical purposes and a growing constituency of individuals acknowledging 
the benefits, this therapeutic botanical provides, the stigma associated with its use is subsiding. A 
legal avenue has opened for savvy chefs and entrepreneurs, who are themselves, authorized 
patients, as a culinary frontier for the development of medical edibles. Many of these chefs are 
experimenting with cannabis, incorporating it as a spice or flavor, to create a sensory food 
experience. However, due to an increased interest in careful cultivation practices, biochemical 
evaluation of the product, and quality control efforts, a viable market for medical edibles has 
developed. 
 This paper investigated edible medical marijuana as a viable frontier and niche market 
from a legal, medical and culinary perspective. It reviewed the etymology and history of 
cannabis, as well as current legal, medicinal and cultivation guidelines.  An overview of four 
states’ dispensary policies, as well as the creative culinary accomplishments of representative 
edible establishments was conducted. The results of this investigation and two surveys: one 
directed to the edible product developers, dispensers, or vendors, and the other directed to 
authorized patients of the dispensaries confirms the emergence of a unique culinary product, its 
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value, increased distribution, and potential for success in this newly developed market. Proving 
that medical marijuana is truly a new frontier in the culinary world. 
As more states consider and enact laws to decriminalize marijuana for medical use, 
careful evaluation of the regulations adopted by those states, which have already enacted these 
laws, appears to be prudent.  Creating consistent, common sense, uniform regulations can benefit 
the state, the patients and producers in this market.   
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Appendix A: Results 
Product Developer/Dispensary Survey 
1. How long have you been in the industry? 
2. When/how did you become interested in edibles? 
3. What do you believe are some of the best qualities marijuana provides in a product? 
4. With which flavors do you find medical marijuana typically goes best with? 
5. Do you use different strains/hybrids of marijuana in different products? If so, what is the 
reason for that?    
6. How do you control the dosage in a product? What procedures do you have to follow?    
7. Does marijuana affect the consistency/texture of a product?   
8. Can your customers taste the plant in the food/do you prefer the taste to come through?   
9. Do you believe the legality issues surrounding marijuana are preventing restaurants and 
other businesses from really taking off?   
10. Do you believe that the risks associated with marijuana outweigh the benefits?   
11. What are some of the major problems you've encountered when it comes to the industry 
and medical marijuana?   
12. What cross-section of the population, based on age and socioeconomic status, are your 
biggest customers? In other words, do you serve a diverse clientele? 
13. What products of yours are most successful? Why do you believe these products are most 
successful?   
14. Do you think the market would support full meals made from edibles?   
15. How is the cannabis incorporated into the edible? 
16. Is the product labeled with the dose amount of THC or the weight of the cannabis? 
17. Does the THC concentration of the cannabis product served need to be noted?R 
18. What lab is used to evaluate the product? 
19. How is the cannabis cultivated? 
20. Is cannabis only allowed to be grown at the dispensary? 
21. Are patients allowed to grow their own cannabis? 
22. Are producers also the legal dispensaries? 
23. Can patients eat at dispensary or are they only allowed to buy and leave? 
24. How is the item served/packaged? 
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Patient/Client Survey 
 
Please Provide the Following: 
1.  Age: a. 18-25 b. 26-35 c. 36-50 d. 51-65 e. 65+ 
2.  Gender:  Male  Female 
       3. Education Level:  
a. High School/GED    b. Some College  c. College Grad   d. Grad./Prof. Degree 
4. Knowing the marijuana product you have access to has been cultivated following strict 
standards is important to you 
a. Yes    b. No 
5. Knowing the marijuana product you are buying is safe as a result of strict cultivation 
standards is important to you 
a. Yes  b. No 
6. Knowing the dose of medicinal marijuana you receive through edibles is scientifically 
determined and carefully monitored is important to you 
a. Yes  b. No 
7. What type of edibles do you prefer? 
a. Savor 
b. Sweet 
c. Beverage 
d. Chocolate/Confection 
e. Other (explain) 
8. Do you prefer that the taste of marijuana is evident or masked? 
a. Evident   b. Masked 
9. Does the presentation of the food matter? 
a. Yes    b. No 
10. What is the reason(s) you are prescribed medical marijuana? Circle all that apply.  
a. Glaucoma  
b. Cancer 
c. Pain Management 
d. Neurological Disorders  
e. As an Appetite Stimulant 
f. Anxiety/Depression 
g. Other (explain) 
11. Do you prefer to use the same dispensary? 
a. Yes    b. No 
12. Do you prefer the flavor of one marijuana strain over another?  
a. Yes   b. No 
Please indicate the strain ____________________ 
13. If legally available, would you frequent a medical marijuana edibles café?  
a. Yes   b. No 
14. Would the atmosphere/decor of the café make a difference to you as a customer? 
a. Yes   b. No 
15. With which flavors do you find Medical Marijuana typically goes best? 
a. Chocolate b. Coffee c. Cheese d. Tea e. Other 
______________________________ 
 
Removed because question was worded 
incorrectly. Left open for too much 
interpretation 
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16. Do you prefer edible products over smoking medical marijuana? 
a. Edible   b. Smoking 
17. Do you prefer having access to medical marijuana edibles over standard medications? 
a. Yes   b. No 
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Appendix B: Dispensary Products and Labels 
 
Bhang Chocolates: Oakland, CA 
 
 
 
KIVA Confections: Oakland, CA 
 
Auntie Dolores: San Francisco, CA 
 
 
Flavors Dose (mg of THC) 
Milk Chocolate 60 
   Dark Chocolate 60 
Salted Toffee Chocolate 120 
Ice Chocolate 180 
Fire Chocolate 180 
Pretzel Chocolate 120 
Cookies and Cream 
Chocolate 
180 
Flavors Dose (mg of 
THC) 
Dark Chocolate 60 
Milk Chocolate 60 
Mint Irish Cream 180 
Tangerine Dark 
Chocolate 
180 
Blackberry Dark 
Chocolate 
180 
Vanilla Chai Milk 
Chocolate 
180 
 
 
Flavors/Types Dose (mg of THC) 
Triple Dosage Brownies 
(Chocolate) 
100 
Triple Dosage Brownies (Mint) 68, 112 
Triple Dosage Brownies 
(Chocolate Peanut Butter) 
59 
Chocolate Chip Cookie Bites 51 
Quad Dosage Caramel Corn 127 
Quad Dosage Chili Lime Peanuts 82 
Quad Dosage Savory Pretzels 127 
Italian Cheese Crackers 184 
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Dixie Elixirs & Edibles: Denver, CO 
 
 
 
 
 
 
 
 
 
 
 
 
 
Canna Elixirs, LLC: Denver, CO 
 
Julie & Kate Baked Goods, LLC: Denver, CO 
 
  
 
 
 
 
 
 
 
 
Flavors/Types Dose (mg of THC) 
Sweet Tea 40 
Sarsaparilla 40 
  Sparkling Grapefruit 40 
Sparkling Blueberry 40 
Sparkling Mandarin 40 
Chocolate Truffles 50, 300 
Krispy Rice Treats 75 
Fruit Lozenges 50 
Dixie Rolls 50 
Dixie Chills (Chocolate 
and Vanilla) 
80 
Flavor/Types Dose (mg of THC) 
Canna Chews (Indica, 
Sativa, Hybrid) 
200 
Canna Drop Cookies 75 
Topical/Sublingual 
Sprays 
200 
Canna Elixirs (Orange 
Cream, Grape Cream, 
Sarsaparilla, Canna Cola) 
100 
Flavors/Types Dose (mg of THC) 
Granola 50, 100 
Roasted Seed Mix 50, 100 
Cannabutters 225 
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Preferred Organic Therapy: Denver, CO 
Carries products from Dixie Elixirs & Edibles, Julie & Kate Baked Goods 
Flavor/Types Dose (mg of THC) 
Dazys: Gummy Bears 80mg 
Edi-Pure Gummies 125. 225 
BlueKudu Rolls 100, 225 
Dr. J’s Kosmic Kookies  250 
Cappuchinno Crisp 150 
Mountain High CBD  Candies 100 
 
Minerva Canna Group: Albuquerque, NM 
 
 
The Verdes Foundation: Albuquerque, NM 
 
 
 
 
 
 
 
Flavors/Types 
Brownies 
Lemon Squares 
Granola Bars 
Lollipops 
Canna-Coke 
Bhang Chocolates (Milk and Dark) 
Cappuccino Crisp 
Flavors/Types Dose (mg of THC) 
Brownies 25 
Lemon Squares 100 
Indica Chocolate 
Cookies 
25 
Sativa Oatmeal 
Cookies 
25 
Lollipops 25 
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Appendix C: Medical Tables 
 
Donald Abrams Standard “Medical Cannabis: Rational Guidelines for 
Dosing” Chart 
 
Strength of Cannabis Daily Dosage Corresponding to 
2.5-90mg THC 
10% .15, 5.55g 
15% .12g, 3.69g 
20% .08g, 2.79g 
25% .04g, 2.25g 
30% .01g, 1.86g 
 
 
 
 
 
 
 
 
 
 
 
 
 
Med. Chart 2 
Lindgren et. al. 415 
Med. Chart 3 
Morgan and Lyn Zimmer 30 
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Appendix D: Recipes 
Majoun, Moroccan “Love Potion” Candy 
Ingredients 
500 grams – 2 cups smen 
3 cups stalks, seeds, and leaves of marijuana (kif, chopped coarsely 
500 grams – 1 lb. chopped, pitted dates 
500 grams – 1 lb. chopped, dried figs 
250 grams – 1/2 lb. raisins 
1 teaspoon ground ginger 
1 teaspoon ground cinnamon 
1 tablespoon anise seed 
1/2 cup each ground almonds and walnuts 
1/2 cup dark honey 
For adding after the candy is cooked: orange flower or rose water to taste 
Method of Preparation: 
Put the herb and smen in a medium pan with water to cover. Bring to a boil, cover, and allow it 
to simmer 2 hours. 
Strain the buttery water out into a large, shallow pan like a roasting pan and discard the herb.  
Refrigerate the pan with herbal butter and water overnight. The cold butter will rise to the top. 
Scoop the herbal butter out and place it in a large pan with the rest of the ingredients. Cook it till 
very thick and brown. Add orange flower or rose water to taste. Pack into clean, dry jars and 
refrigerate. 
 
-From Paula Wolfert’s “Couscous and Other Good Food From Morocco” 
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Appendix E: Images of Marijuana Strains 
 
Image of Cannabis Sativa    Image of Cannabis Indica 
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